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  ABSTRACT 
 
Estrogen plays crucial roles in the pathogenesis of breast cancer. Most of the known 
effects of estrogen signaling are mediated by estrogen receptors (ERs), ERα and ERβ. 
ERα is explored for breast cancer molecular classification and is a target of endocrine 
therapy. The discovery of the second ER (ERβ) including its variants led to a need for 
re-evaluation of the biology of estrogen. This thesis aims to characterize molecular 
aspects of ERβ variants and provide knowledge to elucidate roles of ERβ variants in 
tumorigenesis with focus on breast cancer. 
 
 In PAPER I, we determined the frequency of a novel human ERβ isoform, 
human ERβ548 (hERβ548), which had been demonstrated to display different 
functional characteristics than wild-type ERβ, in several populations including African 
(n = 96), Caucasian (n = 100), and Asian (n = 128) subjects. We did not detect any 
alleles that correspond to hERβ548 in these samples or in additional samples of 
heterogeneous origin. This study concluded, for the first time, that hERβ548 is not a 
common variant in Africans, Caucasians, or Asians. 
 
 In PAPER II, we identified five novel polymorphisms in the ERβ gene in an 
African population. Two of these variants, I3V and V320G were expected to change the 
amino acid sequence of the ERβ protein. Compared to the wild-type ERβ, the V320G 
variant showed significantly decreased maximal transcriptional activity in the ERE 
mediated reporter assay. A pull-down assay and surface plasmon resonance analysis 
revealed that the decreased transcriptional activity of the novel ERβ variant 
hERβV320G was associated with weaker interaction with a co-factor, TIF2. 
 
In PAPER III, we assayed the interaction of several known ligands with mouse 
ERβ1 (mERβ1) and mouse ERβins (mERβ2). A significant difference in ligand binding 
properties was observed. Our results suggest that ligand selectivity and co-activator 
recruitment of ERβ isoforms constitute additional levels of specificity that influence the 
transcriptional response in estrogen target cells in mouse. 
 
In PAPER IV, 202 clinical patient specimens, different non-small cell lung 
cancer (NSCLC) cell lines and transgenic mouse models were used to investigate the 
role of the EGFR signaling pathway for tumorigenesis of NSCLC. We showed that 
activation of the EGFR pathway or hypoxia could promote cell invasion but not 
survival. Furthermore, we demonstrated that the HIF-1α/MET axis is involved in both 
EGFR and hypoxia induced signaling pathways, leading to cancer cell invasiveness.  
 
In PAPER V, a breast cancer cell line BT549 that endogenously expresses the 
hERβ variant hERβ2 in the absence of ERα and wild-type ERβ was used to study the 
effects of hERβ2 signaling on breast cancer cell behavior and associated molecular 
mechanisms. Our data indicate that hERβ2 promotes proliferation and invasion in this 
cell line. A total of 263 genes were identified as hERβ2-upregulated genes and 662 
identified as hERβ2-downregulated genes. hERβ2-regulated genes were involved in 
cell morphology, DNA replication and repair, cell death and survival. Based on our 
data, we hypothesize that effects of hERβ2 on proliferation and invasion were mediated 
via repression of prolyl hydroxylase 3 (PHD3) gene expression and induction of protein 
levels of the hypoxia induced factor 1 (HIF-1α) and MET.  
 
In conclusion, the studies presented in this thesis contribute to the knowledge of 
the function of ERβ variants, and give additional insight into the molecular mechanisms 
underlying cancer cell proliferation and invasion. 
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 INTRODUCTION 1
 
 
 Estrogen receptors  1.1
 
Estrogen plays crucial roles in many tissues in the body, and may be involved in the 
pathogenesis of many endocrine related diseases, such as breast cancer, uterine 
cancer, prostate cancer, autoimmune diseases, osteoporosis and metabolic disorders. 
Most of the effects of estrogen are mediated by the estrogen receptors (ERs). For a 
long time, only one ER was thought to be the receptor that is responsible for 
mediating the effects of estrogen. This receptor is now called ERα. However, in 
1996, another ER, now named ERβ, was reported.  
 
ERs belong to the nuclear receptor (NR) superfamily[1, 2], which includes receptors 
for glucocorticoids, mineralocorticoids, progesterone, androgens, estrogens, thyroid 
hormones, vitamin D and retinoic acid. Upon ligand dependent or independent 
activation, these receptors form dimers and bind to their corresponding response 
element in the regulatory region of their target genes, thus regulating transcription 
[3]. For ERs, the specific sequences of DNA are known as estrogen response 
elements (EREs) [4]. The NRs include four functional domains. The N-terminal 
A/B domain contributes a ligand-independent transcriptional activation function 
(AF-1), a site involved in co-activator binding and transcriptional activation of 
target genes. AF-1 is very active in ERα but has lower activity in ERβ [5]. The 
DNA binding domain (DBD; sometimes referred to as the C-region) contains two 
zinc fingers and mediates sequence specific DNA binding and contributes to 
receptor dimerization. The DBD is linked to the ligand-binding domain (LBD or 
E/F domain) by the D domain or hinge region that is less well conserved and 
characterized. The LBD binds various ligands and is also involved in receptor 
dimerization, nuclear translocation, co-factor binding, and transactivation of target 
gene expression. An activation function 2 (AF-2) localized within this domain 
constitutes a ligand-dependent transactivation function.  
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ERα and ERβ are encoded by separate genes. ERβ has an amino acid identity of 
96% to that of ERα in the DBD, which suggests that ERβ would recognize and bind 
to specific DNA sequences similarly to ERα. The LBD is much less homologous 
between ERβ and ERα, only 59%, also the ligand binding pockets of the two 
receptors are different in structure, indicating the possibility of a different ligand 
spectrum for ERβ versus ERα [6]. The N-terminal AF-1 and C-terminal AF-2 
domains are not well conserved, suggesting that the proteins interacting with ERβ 
for its transcriptional activation functions may be considerably different from those 
interacting with ERα.  
 
The discovery of the second ER, ERβ, led to a need for re-evaluation of the biology 
of estrogen. While the physiological functions of ERβ are still being investigated, 
important insight has been gained, both with regard to its molecular mechanisms of 
action and its role in physiology and disease. At ERE sites, ERβ has weaker 
transcriptional activity than ERα [7-10]. Additionally, there are important DNA 
binding sites for ERs, other than EREs where ERβ shows different, sometimes even 
opposite, effects to those of ERα, e.g. at AP-1 and Sp1 sites [11-14].  
 
The phenotypes displayed by the ERβ knockout (BERKO) animal model, such as 
atretic ovary, hyperplastic prostate and neuronal degeneration, suggest that ERβ 
plays crucial physiological roles. In human, ERα and ERβ show distinct tissue 
distribution. Altered expression of ERβ has been found in several kinds of cancer 
tissues, such as breast cancer, prostate cancer and colon cancer, in which ERβ 
expression is often decreased and sometimes re-gained when the cancer progresses 
to late stage.  
 
Both ERs are widely expressed in different tissues. Notable differences in tissue and 
cellular distribution between ERα and ERβ are shown in Table 1.   
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Table 1   Distribution of ERα and ERβ in human tissues and cells [15-18]  
 ERα ERβ 
Adipose tissue ± ± 
Adrenal + − 
Bladder − + 
Bone + + 
Bone marrow − + 
Brain + + 
Colon − + 
Endometrium + + 
Epididymus − + 
Fallopian tube − + 
Gastrointestinal tract − + 
Heart  + + 
Kidney + + 
Liver + − 
Lung − + 
Muscle  − − 	  
Breast + + 
Ovarian granulosa cells + ++ 
Ovarian theca cells ++ + 
Pancreatic cancer + + 
Pituitary gland − + 
Prostate  ± ++ 
Small intestine − + 
Testes ± + 
Thymus − + 
Uterus ++ + 
Vagina + − 
Vascular endothelium − + 
 
 
 ER ligands 1.2
 
17β-estradiol (E2) is the primary ligand for ER and is the predominant form of 
estrogen hormone in premenopausal women. Estrone (E1) and estriol (E3) are two 
other common ligands with estrogenic activity. They have weaker agonist effects 
than E2 and are found predominantly in postmenopausal women and pregnant 
women, respectively. 
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Selective estrogen receptor modulators (SERMs) refer to a group of compounds that 
act as either an estrogen agonist or antagonist dependent on the cell type and tissue. 
The commonly used SERMs in breast cancer are tamoxifen, roloxifene and 
toremifene. Three mechanisms have been proposed to account for the mixed 
antagonist/agonist effect of SERMs on ERs: (1) distinct ER conformation upon 
ligand binding; (2) differential expression and binding to the ER of coregulatory 
proteins; and (3) differential expression of ERα and/or ERβ subtypes in a given 
target tissue [19]. Fulvestrant/ICI 182,780 is a selective estrogen receptor down-
regulator (SERD), a complete ER antagonist. It works by binding to ER and 
inhibition of its activity by nuclear export and degradation.  
 
ER subtype-selective ligands have been developed. Propyl pyrazole triol (PPT) is a 
well-characterized synthetic ERα agonist, with a 410-fold relative binding affinity 
for ERα versus ERβ [20]. 2,3-bis (4-hydroxyphenyl)-propionitrile (DPN) is a well-
characterized synthetic ERβ agonist, with a 70–300-fold selectivity for ERβ 
compared to ERα [21-23]. Phyto-estrogens (plant-derived) SERMs have steroid 
structures and estrogen-like properties. Genistein is a phytoestrogen, which has a 
greater binding affinity for ERβ than for ERα [23].  
 
 
 ERβ isoforms 1.3
 
Like many other genes, ERβ is expressed as different isoforms, the functions of 
which need to be addressed, in order to fully understand the physiological functions 
of ERβ. Endogenously expressed ER variants may contribute to the diversity of E2 
actions in different tissues. Multiple ERβ isoforms exist as a result of either deletion 
of one or more coding exons, alternative splicing of the last coding exons, or 
alternative usage of untranslated exons in the 5’ region. To date, five full-length 
isoforms, designated ERβ1-5, have been reported in human (Figure 1). The full-
length ERβ1 mRNA is translated from 8 exons, encoding 530 amino acids, while 
the ERβ2-5 transcripts share identical sequences with ERβ1 from exon 1 to exon 7, 
but have unique sequences in place of exon 8. Functional studies have shown that 
ERβ2 can form heterodimers with ERα and ERβ1 on ERE and negatively regulate 
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the transcriptional activity of ERα, but not of ERβ1. ERβ4 and β5 can 
heterodimerize with ERβ1 and enhance its transcriptional activation function in a 
ligand-dependent manner [24]. The expression of ERβ3 appears to be restricted to 
the testis [25]. The properties of these ERβ variants are shown in Table 2. 
 
 
 
 
 
 
 
Figure 1. Structural and sequence comparisons for the human ERβ gene and protein. For the 
gene, exons are indicated with boxes and introns with lines. The numbers above each box designate 
the size of the exons (bp); the numbers below each line indicates the size of the respective introns 
(bp). For the proteins, numbers indicate the amino acids positions in each protein and kDa. 
Functional domains are marked above the protein structure. ERβ variants are formed from 
alternative splicing of the last coding exon. Amino acid sequences of the unique C terminuses are 
listed at the bottom.  
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Table 2	  	  	  Properties of human ERβ variants  
Isoform ERβ1 ERβ2 ERβ3 ERβ4 ERβ5 
E2 binding[7, 24, 26] + − + ± ± 
ERE binding[1, 27] + ± NA + ± 
Dimer/ERα[1, 8, 25] + + + + + 
Dimer/ERβ1[1, 24] + + + + + 
Homodimers[24] + − NA - - 
Inhibits ERα function [8] + + + NA + 
Enhance  ERβ function*[1]  − NA + + 
Nuclear localization + + NA + + 
Cancers[28-33] CC, BC, 
TC, OC 
BC, PC, EC, 
CC,GC, OC, TC 
  BC, OC 
* Enhance ERβ1-induced transactivation in a ligand-dependent manner 
+, interaction; -, no interaction; NA, information not available; BC, breast carcinoma; PC, prostate 
carcinoma; EC, endometrioid carcinoma; CC, colorectal carcinoma; GC, gastric adenocarcinoma; 
OC, ovary carcinoma; TC, thyroid cancer. 
 
 
More specifically, the following ERβ isoforms have been characterized in this 
thesis.  
 
 
 Potential N-terminus extended variant, human ERβ548 1.3.1
 
Human ERβ (hERβ) cDNA was cloned as a protein of 485 amino acids in length in 
1996 [7, 8]. In 1998, the N-terminus of hERβ was extended with 45 extra amino 
acids. This protein is now referred to as hERβ1 [1, 2]. hERβ1 has been considered 
as the full length hERβ. However, a hERβ cDNA that corresponds to a protein of 
548 amino acids was cloned from human testis cDNA. It was suggested that a 
genomic polymorphism corresponding to an insertion of an extra A-T base pair 
places an upstream ATG in frame with the rest of the coding sequence. The authors 
speculate that this might represent a polymorphism in human populations [34]. 
However, our study of African, Caucasian and Asian populations failed to support 
that human ERβ548 exists [35]. 
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 hERβ2 1.3.2
 
The most studied variant of hERβ, hERβ2, is the result of alternative splicing, 
exchanging exon 8 for an alternative exon which has 26 unique amino acids. hERβ2 
lacks the AF-2 core region and has undetectable affinity for ligands. It acts as a 
dominant-negative inhibitor of ERα [1]. It has been shown that hERβ2 
heterodimerizes with ERα and inhibits ligand induced ERα transcriptional activity 
by inducing proteasome-dependent degradation of ERα [36]. hERβ2 was also 
shown to inhibit recruitment of ERα to estrogen-responsive promoters, leading to 
suppression of the expression of ERα regulated genes including CCND1 and 
CDKN1A.  
 
Evidences suggest that in contrast to hERβ1, hERβ2 has proliferative characteristics 
and is associated with cell proliferation and invasion and aggressive phenotype [37]. 
The expression of hERβ2 is widespread and has been reported to have higher 
expression in cancer tissue compared to normal tissue for breast, colorectal, prostate 
and non-small cell lung cancer [28, 33, 38, 39].  
 
 
 rERβ2 (rERβins) 1.3.3
 
In rodents, many isoforms have been reported. The most well studied isoform of 
rodent ERβ is rodent ERβins (rERβins), which has an 18 amino acid insertion in the 
LBD region. Interestingly, rERβins is expressed in most tissues of rat and mouse. 
Furthermore, it has markedly reduced ligand binding, requiring 100 to 1000 fold 
higher E2 concentrations for maximal activation compared to wild-type ERβ and, at 
physiological E2 concentrations (with the exception of the ovary where E2 
concentrations are higher), it can suppress E2 dependent ERα and ERβ mediated 
activation of gene expression [40-42]. It is interesting to speculate that rERβins is 
designed to activate gene expression only at the high concentrations of E2 present in 
the ovary. Alternatively, it might be designed to respond to other ligands. 
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 Expression of ER variants in association with diseases  1.4
 
ERβ expression has been found in normal breast tissue and breast cancer. In normal 
breast, ERα exists in epithelial cells while ERβ is found in both epithelial and 
stromal cells. ER expression changes during breast cancer progression. ERα levels 
increase while ERβ levels decrease in breast cancer compared to normal breast, and 
ERβ level is negatively correlated with aggressive clinical features of breast cancer. 
In breast cancer expressing both ERs, estrogen could act via ERβ to moderate ERα 
driven proliferation.  
 
Increased expression of ERβ2 correlated with the level of tumor inflammation and 
grade, respectively, in breast cancer [43]. Several studies have indicated that ERβ2 
is associated with poor clinical outcome and poor survival in human cancers. 
Furthermore, ERβ2 expression correlates with aggressive phenotypical features. In 
prostate cancer, ERβ2 was shown to correlate with poor prognosis and could 
promote cancer cell proliferation and invasion [37, 38]. In contrast, one research 
group reported decreased expression of ERβ2 in colon cancer compared with the 
normal colon tissue [30].  
 
 
 ERβ1 expression in correlation to clinical features 1.4.1
 
Many studies indicated that ERβ1 expression is a predictor of favorable outcome. 
Generally higher levels of ERβ1 expression were associated with longer overall 
survival and disease free survival [44-46], better response to anti-estrogen therapy 
such as tamoxifen [47, 48], lower grade, negative lymph-node status and smaller 
tumor size [49-51]. 
 
Twenty nine out of 43 studies showed that ERβ1 is highly expressed in normal 
tissues relative to tumors [28, 31, 52-55] and that lower ERβ1 expression in tumors 
is associated with poor differentiation, invasive properties, metastasis and high 
stage of tumor [33, 43, 56-59]. Consistent with these findings, other studies showed 
that higher expression of ERβ1 is associated with low biological aggressiveness, 
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favorable clinical outcomes, better response to endocrine therapy and better survival 
[15, 29, 44, 46, 48, 50, 51, 60-67]. However, nine studies did not find any 
association between ERβ1 expression and pathology parameters, major clinical 
outcomes or cancer stage [15, 68-75].  
 
Although it seems ERβ1 is a biomarker for favorable clinical outcomes, some 
studies indicated that the ERβ1 expression level is higher in tumors compared to 
normal tissues [76]. One study of 167 invasive breast cancers from postmenopausal 
women showed that high ERβ1 expression was associated with elevated cell 
proliferation and not correlated with clinical outcomes in the absent of ERα [71]. 
Moreover, ERβ1 was found to be positively correlated with aggressive clinical 
features in a study of 926 breast cancer patients [77]. Another study showed the 
enhanced nuclear and cytoplasmic ERβ1 expression was associated with advanced 
stage in colon cancer [76]. ERβ1 expression was also shown to correlate with poor 
cell differentiation and poor overall survival in a Chinese population [78]. 
Furthermore, few studies showed that ERβ1 promotes cell proliferation in ERα-
negative breast cancers [71, 79]. Thus, at present the relation of ERβ1 to 
clinicopathological parameters is unclear and more studies are needed to conclude 
physiological function of ERβ1 in breast cancer.  
 
The function of ERβ1 can be different when it is expressed alone compared to when 
it is co-expressed with other ERs. Additionally, the function of cytoplasmic ERβ 
isoforms may differ from nuclear ERβ isoforms. Furthermore, ERβ isoforms have 
been shown to exert tissue-selective functions and may also connect with hormonal 
status [80].  
 
 
 ERβ2 expression in correlation to clinical features 1.4.2
 
Many recent studies explored the function of ERβ2 in cancer. 22 of the above 41 
studies also examined ERβ2 expression. These studies showed ERβ2 differently 
correlated to clinical features compared with ERβ1. Five out of 22 studies did not 
find a correlation between ERβ2 expression and clinical outcomes or survival. Ten 
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studies showed that ERβ2 correlated to better outcomes. Seven studies showed that 
ERβ2 was highly expressed in tumor, and its expression was increased in advanced 
stages of tumors, associated with invasiveness, metastasis and poor survival [15, 29, 
33, 43, 48, 53, 64, 73, 81] .  
 
Lymphocytes express high levels of ERβ2, which may contribute to the high 
expression level of ERβ2 in tumors with inflammation [43]. The cellular 
localization of ERβ isoforms determines tumor outcomes. Thus nuclear ERβ2 
expression is associated with good outcome whereas cytoplasmic ERβ2 expression 
is associated with worse overall survival [75]. 
 
Most of the studies on the expression of ERβ2 have been analyzed at the mRNA or 
protein levels, in the latter case based on immunohistochemistry (IHC). Different 
ERβ2 antibodies may influence the results. All these have to be taken into account 
when comparing results from different studies. At present the relation of ERβ2 to 
clinical features is still unclear and more studies are needed to make conclusions 
about the contribution of ERβ2 expression in cancer.  
 
 
 ERβ SNPs in association with diseases 1.4.3
 
Around 720 single nucleotide polymorphisms (SNPs) have been identified in the 
ERβ gene [82]. They locate to the 5’UTR, promoter region, introns, 3’UTR, and 
coding regions. SNPs in coding regions and regulatory regions may affect gene 
and/or protein function and SNPs in the 3’UTR may contribute to translatability and 
mRNA transcript stability [83, 84]. rs4986938, rs928554 and rs1256049 are 
frequent ERβ polymorphisms. None of these SNPs change the amino acid sequence 
of the ERβ protein [85-87]. Polymorphisms in ERβ have been correlated to breast 
cancer [85-88], ovulatory dysfunctions [89], bone mineral density [90], 
hypertension [91], bulimic disease [88] and androgen levels [92].  
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 Breast cancer molecular subtypes 1.5
 
Breast cancer is a common cause of cancer death among women. It is a disease 
with different morphological features and clinical behaviors, and 5 subtypes 
(Luminal A, Luminal B, normal breast like, human epidermal growth factor 
receptor 2 (HER2) enriched and basal-like breast cancer) have been defined 
according to microarray gene profiling based classification [93] (Table 3). 
Approximately 60-80% of basal-like breast cancers and 71% of claudin low breast 
cancer correspond to triple negative breast cancers (TNBCs), which are 
characterized by a lack of expression of ER, progesterone receptor (PR) and HER2. 
TNBC, which constitutes 15–25% of all breast cancers, is a cancer with aggressive 
phenotypes and the worst prognosis among breast cancer subtypes. It affects mostly 
in younger age or premenopausal groups and the incident rate is high in African 
American [94]. TNBC lacks effective targeted therapies. Furthermore, TNBC lacks 
any known predictive biomarkers and often develop distant metastasis in tissues 
such as brain and lung.  
 
 
Table 3   Molecular classification of breast cancer 
Subtypes 
[95] 
Markers Incidence 
rate [94, 95] 
Prognosis Therapy  
ER PR HER2 Other markers    
Luminal A + + − Low Ki67 40-62% Good prognosis, 
less 
invasiveness 
Hormonal 
therapy 
Luminal B + ± ± HER2− with high Ki67 9-20% Moderate  Hormonal, 
chemotherapy, 
HER2 blockade 
Basal-like − − − CK5/6+ and/or EGFR+ 8-20% Poor Chemotherapy 
HER2+ − − + ? 4-16% Poor-moderate Chemotherapy, 
HER2 blockade 
Normal like − ? ? ? 6-10% Moderate  ? 
Claudin low  − − − Enrichment for EMT 
markers, immune response 
genes and cancer stem 
cell-like 
7-14% Poor ? 
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 Therapeutic treatment of breast cancer 1.5.1
 
Many factors can influence the effect of therapeutic treatment of breast cancer such 
as the type of breast cancer, the stage of the cancer, the status of ER, PR and HER2, 
patient age, menopausal status, family breast cancer history and the status of ER 
variants.  
 
The main types of treatment for breast cancer are surgery, radiation therapy, 
chemotherapy, hormone therapy and targeted therapy. Among them, surgery and 
radiation therapy are local therapies, which treat the tumor at the local site without 
affecting the whole body. Chemotherapy, hormone therapy and targeted therapy are 
systemic therapies, which will affect cancer cells in the whole body. Sometimes 
breast cancer patients also need neoadjuvant therapy before surgery to make the 
tumor shrink and allow for a less extensive surgery and/or adjuvant therapy after 
traditional treatments in order to prevent cancer cells coming back.  
 
Hormonal therapy is targeted to inhibition of estrogen production and ER action 
(Figure 2). It is used as an adjuvant therapy in ERα-positive breast cancers. 
Tamoxifen is the oldest, most well-known and prescribed SERM, which can 
interfere with estrogen binding to ERs in the breast. Aromatase inhibitors, e.g., 
anastrozole, work by inhibiting estrogen synthesis. An aromatase inhibitor is the 
hormonal therapy to start with for postmenopausal women. Pure antiestrogen such 
as fulvestrant can also be used to block estrogen signaling pathways. Small 
molecules that block co-factor binding or inhibit ERα binding to ERE are 
considered as novel ER inhibitors with significant clinical potential [96, 97].  
 
70% of ERα-positive breast cancer patients response to hormonal therapy. 
However, 30-40% of patients initially responding to hormonal therapy eventually 
relapse as a significant fraction of breast cancers develop endocrine therapy 
resistance. Identifying key regulators and pathways involved in ER signaling in 
resistant breast cancer would provide opportunities for a new generation of 
therapeutic targets in breast cancer. 
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Figure 2. Therapeutic strategies targeting ER action in breast cancer. One treatment option is to 
block ER action by using selective estrogen receptor modulators (SERMs) such as tamoxifen to 
compete with estrogens for binding to ER. Fulvestrant/ICI 182,780 is a complete ER antagonist, 
which binds to the ER and promotes its degradation. Other forms of therapy include using 
aromatase inhibitors to inhibit the synthesis of estrogen production, using small molecules and 
peptides to block co-activator binding to liganded ER, using monoclonal antibodies against HER2 
such as trastuzimab or targeting tyrosine kinases directly by tyrosine kinase inhibitors such as 
gefitinib to inhibit non-ligand activated ER action. 
 
 
 ER signaling pathways 1.6
 
ERs are transcription factors including two transcriptional activation domains. The 
classical ER signaling occurs through ligand binding to the LBD of the receptor and 
induction of ligand specific conformational changes in the ER protein. The 
receptors form dimers and bind to DNA at EREs through their DBD. Most of the 
known estrogen derived effects are mediated via this direct interaction of ERs with 
DNA. Interaction of ERs with DNA is followed by recruitment of co-activators, 
leading to the induction of chromatin remodeling and increased transcription of 
estrogen targeted genes.  
 
The non-classical genomic ER signaling pathway is mediated by the tethering of ER 
to DNA through protein-protein interactions with other transcription factors such as 
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AP-1 and Sp1, a so-called tethering mechanism (Figure 3). This pathway of ER 
action is also called the indirect ER signaling pathway. Furthermore, ER can be 
activated in a ligand independent way. Growth factor signaling or stimulation of 
other signaling pathways leads to activation of kinases that can phosphorylate the 
dimerized intracellular ERs, which subsequently active target genes and trigger 
downstream signal transduction cascades even in the absence of ligand.  
 
ER signaling can also occur through a non-genomic pathway, which refers to that 
ER can regulate gene expression without binding directly to DNA. This action has 
been shown to involve the activation of downstream cascades such as PKC, PKA, 
and MAPK via membrane-localized ERs. In addition, an orphan G protein-coupled 
receptor (GPR30) in the cell membrane has been reported to mediate nongenomic 
ER signaling. The activities of GPR30 in response to estrogen were shown to be 
mediated through its ability to induce expression of ERα36, a novel variant of ERα, 
which in turn acted as an extranuclear ER to mediate nongenomic estrogen 
signaling [98].   
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Figure 3. Schematic models illustrating ER signaling pathways [99]. 1, 2, and 4 illustrate the 
genomic action in the nucleus, while 3 illustrates the non-genomic action in the cytoplasm. 1. 
Estrogen binds to ERs. Liganded ERs form dimers and bind directly to estrogen response elements 
(EREs) in target genes in the nucleus. 2. Ligand/ER complexes tether to other transcription factors, 
bound to their response elements (RE) in target genes, to activate the transcription of non-ERE 
containing genes. 3. Ligand activated membrane bound ERs in complex with other factors functions 
as ‘second messengers’ (SMs) act to activate non-genomic signaling cascades. 4. Growth factor 
(GF) activated protein kinase cascades phosphorylate and activate ERs leading to binding to EREs 
in target genes in the nucleus, resulting in ligand independent activation. 
 
 
 Signaling pathways in cancer biology  1.7
 
Cancer is the result of cell growth and division out of control starting to invade 
neighboring tissues and metastasize. Proliferation potential, cell growth out of 
control (insensitivity to growth inhibitory signals), apoptotic escape, limitless 
replicative potential, angiogenesis and invasion/metastasis are the six hallmarks in 
cancer progression [100]. Many complex signal transduction processes are involved 
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in cell growth and survival. Disruption of those signaling pathways may cause 
cancer. Over 40 pathways have been demonstrated to relate to cancer biology 
including epidermal growth factor receptor (EGFR) signaling, PI3K/AKT signaling, 
Ras/Raf/Mek signaling and MET signaling. Some of these signaling pathways will 
be discussed further below. 
 
In epithelial cancers such as breast cancer, metastasis is thought to occur start with 
epithelial-to-mesenchymal transition (EMT). EMT is a process of loss of epithelial 
phenotypes and gain of new migratory and invasive growth phenotypes by 
cytoskeleton rearrangements and cellular adhesion, structure and morphology 
alternation. Epithelial markers on the cell surface such as E-cadherin or integrins are 
replaced with mesenchymal markers, such as vimentin, N-cadherin, or fibronectin. 
During the process of EMT, cells lose their characteristic epithelial traits and 
instead gain migratory potential and detach from the basal membrane [101].  
 
 
 ER signaling in tumorigenesis  1.7.1
 
Evidence from the clinic, cell line based in vitro models and in vivo animal models 
revealed that estrogen and ERs contribute to tumorigenesis, including breast, 
uterine, colorectal, prostate, lung, pancreatic and ovarian cancers [102-108]. 
Aberrant estrogen signaling results in disruption of the cell cycle, apoptosis and 
DNA repair, which are implicated in cancer initiation and progression and may also 
influence the response to cancer therapy [109, 110]. E2 was reported to enhance 
ovarian cancer migration through ERα mediated EMT. Snail, Slug and E-cadherin 
were identified as transcriptional targets of ER signaling in EMT [111]. 
 
Many studies indicated that ER subtypes play different roles in tumorigenesis and in 
response to cancer therapy. ERβ1 acts as a tumor suppressor in cancer biology 
[103]. Activated ERβ1 signaling by introducing ERβ1 or its agonists has anti-
proliferative effects. Recent evidence showed that overexpression of ERβ1 exerts 
tumor repressive functions in human malignant pleural mesothelioma via EGFR 
inactivation and affects the response to Gefitinib, an EGFR inhibitor [112]. ERβ1 
knockdown in ERβ1 positive cells confers a more invasive phenotype, increases 
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anchorage independent proliferation and elevates the constitutive activation of 
EGFR-coupled signal transduction pathways [112]. In ERα-positive breast cancer 
cells, ERβ1 expression was found to reduce Akt activation through down regulation 
of HER2/HER3 signaling. On the contrary, in one study of prostate cancer cells, 
ERβ2 was shown to increase proliferation and up-regulate factors known to be 
involved in bone metastasis, whereas ERβ1 inhibited these parameters [37].  
 
In prostate cancer, ERβ1 represses basal-like breast cancer EMT transition by 
destabilizing EGFR [113]. In breast cancer, loss of TBK1 was reported to drive 
induction of EMT through down regulating ERα expression in ERα-positive cancer. 
Furthermore, ERβ1 was reported to inhibit EMT and invasion in TNBC in vitro or 
in vivo in a zebrafish model [113]. ERβ1 inhibits EMT through up-regulation of 
miR-200a/b/429 and the subsequent repression of ZEB1 and SIP1, which in turn 
leads to increased expression of E-cadherin [113].  
 
ERα seems to contribute to tumor progression primarily by having a mitogenic role 
to stimulate cell proliferation. ERα promotes breast cancer cell proliferation both in 
vivo and in vitro by increasing the expression of MYC, cyclin D1 (CCND1) to 
facilitate cell cycle progression [114-116]. In the absence of ligand, MAPK- and 
PI3K-driven phosphorylation can enhance ERα transcriptional activity and induce 
breast cancer cell proliferation [117, 118]. ERα also plays a role in EMT. In breast 
cancer cells, ERα interacts with AIB1 (also known as SRC-3), which could bind to 
the ERα-binding site on the Snial1 promoter, resulting in increased expression of 
Snail1 and the subsequent repression of E-cadherin [119, 120]. 
 
Recent studies also found that ERα extranuclear signaling is involved in breast 
cancer cell migration and metastasis through activation of kinase cascades. For 
examples, ERα extranuclear signaling promotes stimulation of the Src kinase, 
MAPK, PI3K, and protein kinase C pathways in the cytosol. Many of these kinases 
activated by ERα extranuclear signaling have been shown to be implicated in breast 
cancer metastasis [121, 122]. However, the molecular mechanisms by which 
extranuclear ER exerts its function remain unclear.  
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 EGFR 1.7.2
 
The epidermal growth factor receptor (EGFR, HER-1, c-erbB-1) is a subfamily of 
four closely related receptor tyrosine kinases (RTKs): EGFR (ErbB-1), HER2/c-neu 
(ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). These four transmembrane growth 
factor receptors share similarities in structure and function. The HER2 gene is 
amplified and HER2 is overexpressed in 25% to 30% of breast cancers, increasing 
the aggressiveness of the tumor [123]. Lack of response to endocrine therapy, 
together with increased metastasis and poor survival, has been shown to be 
associated with over-expression of EGFR and HER2 in clinical breast cancer [124, 
125]. 
 
There are two major binding ligands, epidermal growth factor (EGF) and 
transforming growth factor-alpha (TGF-α) that can activate EGFR. Ligand binding 
to EGFR results in receptor homo- or hetero-dimerization (with one of the HER 
family of receptor tyrosine kinases) followed by autophosphorylation of the tyrosine 
kinase domain. Phosphorylated tyrosine residues serve as binding sites for the 
recruitment of signal transducers and activators of intracellular substrates. The 
Ras/Raf/MAPK and PI3K/Akt pathways are the major signaling routes for the HER 
family, including EGFR. These pathways control several important biologic 
processes, including cellular proliferation, invasiveness, angiogenesis and inhibition 
of apoptosis [126-128]. EGFR signaling pathways are shown in Figure 4. 
 
Genetic mutations or gene amplifications in RTKs and their downstream factors 
result in aberrant cell signaling often leading to cancer cell growth and/or resistance 
to cancer therapies [129, 130]. The well-studied RTKs mutation is the EGFR-
activating mutation in non-small cell lung cancer (NSCLC). Certain mutations in 
the EGFR tyrosine kinase domain including an amino acid substitution at exon 21 
(L858R) and in-frame deletions in exon 19 were found to be predictors of clinical 
response to EGFR tyrosine-kinase inhibitors (TKIs). EGFR-activating mutations 
represent a subset of NSCLC patients and are predictors of EGFR TKI treatments 
[131].  
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Figure 4. EGFR and MET cell signaling pathways. EGFR activates several major downstream 
signaling pathways, including Ras–Raf–Mek and the pathway consisting of phosphoinositide 3-
kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR), which in turn may have an effect 
on proliferation, survival, invasiveness, metastasis, and tumor angiogenesis. These pathways may 
also be modulated by other receptor tyrosine kinases, such as the HGF/MET signaling pathway.  
 
 
 MET 1.7.3
 
The MET oncogene, encoding for the tyrosine kinase receptor for hepatocyte 
growth factor (HGF) is over expressed in various cancer cells. The MET tyrosine-
kinase receptor is an established mediator of cancer cell invasiveness. MET can 
increase the viability of cancer cells [132]. Cross talk between the EGFR and MET 
has been identified in several tumor types, with HGF being able to transactivate 
EGFR and conversely EGFR ligands activating MET. EGFR inhibitors have been 
shown to attenuate HGF-mediated proliferation, migration and invasion of several 
breast cancer cell lines in vitro. HGF and/or MET expression increase with tumor 
progression and each is independently associated with poor prognosis. HGF/MET 
expression gradually increases during breast cancer progression from normal breast, 
carcinoma in situ to invasive carcinoma [133], suggesting their involvement in the 
malignant progression in breast cancer. Tumor hypoxic areas show MET 
overexpression [134]. The HGF/MET pathway is important in basal-like breast 
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cancer and is considered as a strong candidate target for treating premalignant 
basal-like lesions [135]. MET is also associated with invasion and metastasis in 
breast cancer. Its expression and activation correlate with tumor hypoxia and HIF-
1α activation [136]. When MET is inhibited, hypoxia induced invasive growth was 
prevented [126, 134]. Previous findings also showed that MET levels can be 
regulated by HIF-1α [126].  
 
 
 HIF-1α 1.7.4
 
Tumors are surrounded by a low-oxygen environment, making the hypoxia-induced 
factor HIF-1 signaling important for cell survival. HIF-1 is a heterodimeric protein 
consisting of two subunits, HIF-1α and HIF-1β. HIF-1α, which forms a DNA-
binding heterodimer with the constitutively expressed HIF-1β subunit, is stabilized 
and activated under hypoxia. Upon activation, HIF-1 binds to the hypoxia response 
elements of target genes. The activity of HIF-1 is regulated through the stabilization 
and activation of HIF-1α.  
 
HIF-1α modulates the expression of 1-5% of human genes, including genes 
involved in glycolysis, cell cycle control, proliferation, invasion, angiogenesis and 
metastasis [137]. Aberrant signaling via pathways such as Ras-MAPK, Src, or 
PI3K/mTOR increases HIF-1α expression under normoxic and hypoxic conditions. 
PI3K/AKT activation was also reported to increase HIF-1α stability through 
mTOR, particularly in breast cancer [137]. HIF-1α is associated with poor 
prognosis and therapy resistance in cancer and is also a major determinant of 
invasion and metastasis in a wide variety of tumor types [138].  
 
 
 PHDs 1.7.5
 
Prolyl hydroxylases domain-containing proteins (PHDs) regulate the appropriate 
balance of HIF-1α protein at the post-translation level. PHDs are oxygen sensors 
that can target two proline residues (p402 and p564) in two -Leu-X-X-Leu-Ala-Pro 
sequences in the oxygen-dependent degradation domain of HIF-1α in the presence 
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of oxygen. The hydroxylated HIF-1α can be recognized by the tumor suppressor 
von Hippel-Lindau (pVHL) protein, followed by polyubiquitination by the VHL E3 
ubiquitin ligase, which targets proteins for degradation by the proteasome. β2-
adrenergic receptor, which is a prototypic G protein-coupled receptor, was 
identified as a new hydroxylation substrate of PHD3 [139]. The discovery of this 
new target helps us to better understand the functionality of PHDs and the cellular 
response to oxygen. 
 
In pancreatic cancer, PHD2 exerts tumor-suppressive acitivity [140]. In breast 
cancer, high PHD2 expression has been shown to be associated with better survival 
[141]. Similarly high PHD3 expression is correlated with good clinical prognosis 
markers such as lower tumor grade, smaller tumor size and lower proliferation 
[141]. PHD3 may also be a critical regulator of apoptosis in sympathetic neural 
development and breast cancer [141, 142]. In pancreatic cancer, high PHD2 
expression is associated with lymph node negativity and PHD2 can suppress 
angiogenic cytokines to inhibit angiogenesis mediated tumor growth and invasion 
[140]. Interestingly, ERβ was reported to sustain epithelial differentiation by 
promoting PHD2 expression via direct binding to an ERE in the 5′ UTR of the 
PHD2 gene in prostate cancer cell line [143].  
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 AIMS OF THE THESIS 2
 
 
ERβ is expressed as different isoforms, the functions of which need to be addressed, 
in order to fully understand the physiological functions of ERβ. The overall aim of 
this thesis was to clarify functionality and mechanisms of the ERβ variants, 
focusing on breast cancer. 
 
The specific aims were: 
PAPER I To investigate the frequency of the reported hERβ548 variant in 
human populations. 
PAPER II To identify and characterize hERβ variants in an African American 
population. 
PAPER III To characterize the function of mERβ2. 
PAPER IV To investigate the mechanisms of EGFR signaling involved in cell 
invasiveness in NSCLC. 
PAPER V To investigate the effects of hERβ2 on breast cancer cell 
proliferation and invasion, including characterization of pathways that may 
contribute to the observed phenotypes with specific focus on the PHDs and HIF-1α 
pathways. 
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 METHODOLOGICAL CONSIDERATIONS 3
 
 
 WAVETM technology 3.1
 
WAVETM is a high-performance liquid chromatography (HPLC) based technology 
to detect mutations, based on the resolution of hetero duplexes and homo duplexes 
by HPLC. Individuals who are heterozygous for a mutation or polymorphism have a 
1:1 ratio of wild-type and mutant DNA. A mixture of hetero- and homo-duplexes is 
formed when PCR products are annealed by heating to 95°C and cooling slowly. 
DNA from individuals who are homozygous for a mutant allele is detected by the 
addition of wild-type DNA. Thus, each sample is analyzed both in the presence and 
absence of a wild-type PCR product. The ability of the WAVE method to resolve 
hetero-duplex DNA from homo-duplex DNA in minutes makes it a powerful tool in 
the field of mutation detection. We used this technology in PAPER I to assay a 
suggested polymorphism in the 5’ UTR of hERβ that would generate an upstream 
ATG in frame with the rest of the coding sequence to generate a longer form of 
hERβ, hERβ548. We also used this technology in PAPER II to identify SNPs in 
hERβ in an African population. In the latter study, samples with aberrant HPLC 
profiles were subjected to DNA sequencing and compared with the published 
genomic sequence of the hERβ gene. 
 
 
 Quantitative polymerase chain reaction  3.2
 
Quantitative polymerase chain reaction (qPCR, real-Time PCR) is a widely used 
sensitive method for accurate quantification of mRNA at low throughput. It 
includes double-stranded DNA-binding dyes for detection of amplified DNA 
(SYBR Green dye) or fluorescent dye labeled probe methods for detection of 
amplified DNA (TaqMan probes). In PAPER IV, in order to get accurate results, 
we used the TaqMan probe method, which has both high specificity and 
reproducibility. The primary disadvantage of the SYBR Green dye method is that it 
detects all double-stranded DNA, including non-specific reaction products. In 
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PAPER V, we compared both methods for some experiments and got similar results 
and then mainly used the SYBR Green method in this study.  
 
In qPCR, the accumulation of specific amplified PCR products in “real time” during 
PCR amplification was detected. The first cycle at which point when the fluorescent 
signal is above the background signal is called the “Ct” or threshold cycle, which is 
used to quantify the number of substrates present in the initial template quantity. 
We used comparative CT method to calculate the relative fold change. The amount 
of target, normalized to an endogenous reference and relative to a control, is given 
by: 2-ΔΔCT.  
ΔCT = CT target – CT endogenous house keeping 
ΔΔCT = ΔCT test sample – ΔCT control sample 
 
 
 Gene expression microarray analysis 3.3
 
DNA microarray is a technology that can monitor global gene expression on a 
single array giving researchers the opportunity to get a better picture of the 
interactions among thousands of genes simultaneously.  
 
Two Affymetrix expression array types were used in our studies. In PAPER IV, we 
used the Affymetrix GeneChip Human Genome U133A (HG-U133A) array which 
contains approximately 45,000 probe sets representing more than 39,000 transcripts 
derived from approximately 33,000 well-substantiated human genes.  This array 
was used to perform global gene expression analysis on 53 gene arrays representing 
53 NSCLC cell lines.  
 
In PAPER V, we used the Affymetrix Human Gene 1.1 ST arrays, which contain 
probes for 33299 gene sequences to identify global target genes for hERβ2. A cut-
off fold of 1.5 and p value < 0.05 were used to define regulated genes. The total 
regulated genes were loaded and analyzed using Ingenuity Pathway Analysis 
software (IPA) (Ingenuity), a bioinformatic tool for network, functional and 
pathway analysis. Pathway analysis identifies specific biological processes. Genes 
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were ranked and mapped to networks in IPA. Important networks related to 
biological function are given and scored. The most significantly regulated genes 
were shown and classified upon molecular and cellular function. 
 
 
 Cell lines 3.4
 
Several immortalized cell lines from different tissues have been used in this thesis. 
Cell lines are considered as standard in vitro model systems due to their ease of 
cultivation and manipulation.  
 
In PAPER IV, NSCLC cell lines H3255, H1975, H1993, and HCC827, A549 and 
Calu-6 were used. H3255, H1975 and HCC827 represent cell lines bearing EGFR-
activating mutations. The HCC827 cell line is from a pulmonary adenocarcinoma, 
which harbors an in-frame E746 - A750 deletion in exon 19 in the EGFR tyrosine 
kinase domain. H3255 was initiated from malignant cells isolated from the pleural 
effusion. It carries a L858R point mutation in exon 21 in the EGFR tyrosine kinase 
domain. H1975 was isolated from a lung adenocarcinoma with an L858R EGFR 
activating mutation and a T790M mutation in exon 20, which made it resistant to 
EGFR TKIs. A549 is a human pulmonary adenocarcinoma epithelial cell line, with 
wild-type EGFR and a KRAS mutation. It was used as a cell line with non-EGFR 
mutation in the study. Calu6 is a human pulmonary adenocarcinoma epithelial cell 
line, which is wild-type for EGFR. H1993 is derived from a metastatic site of a 
female pulmonary adenocarcinoma patient with MET gene amplification. NIH-3T3 
cells expressing wild-type EGFR or EGFR bearing the L858R mutation or the 
deletion mutant ΔL747-S752del [144] were obtained from Dr. Jeffrey Engelman 
(Dana-Farber Cancer Institute). 
 
In PAPER V, the breast cancer cell line BT549 was used. BT549 is of epithelial 
origin and derived from invasive ductal carcinoma. BT549 harbors a p53 R249S 
mutation and pTEN mutation. 
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 Generation of artificial mutations  3.5
 
Mutagenesis is the process by which the genetic information is changed. It is an 
important technique in the laboratory to examine the effects of mutations. In this 
thesis, we use the QuickChangeTM XL Site-Directed mutagenesis kit (Stratagene, La 
Jolla, CA) to generate several artificial mutations for further functional studies. The 
sequences of the artificial mutations were confirmed by DNA sequencing. In 
PAPER I, in order to validate the method for screening the novel N terminus 
extended isoform in different populations, hERβ548 plasmid that has the reported 
extra nucleotide of the ERβ gene was generated from hERβ530. In PAPER II, In 
order to study the function of ERβ SNPs existed in African samples, hERβ105AèG 
and hERβ1057TèG plasmids were generated from hERβ530. In PAPER IV, HIF-1α 
mutant with proline to alanine in two positions 402 and 564 (HIF-1α P402A; 
P564A) were generated from the wild-type HIF-1α. This form is stabilized in 
normoxia because of the loss of VHL-mediated polyubiquitination and subsequent 
degradation. Also stable cell lines expressing wild-type EGFR or EGFR bearing the 
L858R mutation or the deletion mutant ΔL747-S752del were used.  
 
 
 Small interfering RNA (siRNA) 3.6
 
SiRNA is also known as silencing RNA or short interfering RNA. It is a double-
stranded RNA, about 20-25 base pairs long, which interferes with the expression of 
genes having the complementary nucleotide sequence. SiRNAs correspond to short 
double-stranded RNAs with phosphorylated 5' ends and hydroxylated 3' ends with 
two overhanging nucleotides. 
 
siRNAs are important tools for validating gene function. siRNAs can be introduced 
into the cell by transient transfection. In PAPER IV, commercial available 
siGENOME Non-Targeting siRNA pool against EGFR, MET, HIF-1α and scramble 
control were introduced by transient transfection to study the effect of EGFR 
signaling and MET-HIF-1α axis in EGFR or hypoxia induced NSCLC cell 
invasiveness. In PAPER V, multiple siRNAs targeting hERβ2 and a scramble 
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control were introduced into a TNBC cell line BT549 to study the function of 
hERβ2.   
 
 
 Cell proliferation assay 3.7
 
The MTT assay is a common used colorimetric assay for determining the number of 
viable cells by measuring the cellular metabolic activity via NAD(P)H-dependent 
cellular oxidoreductase enzymes that reduce the tetrazolium dye, MTT, to its 
insoluble form formazan, giving a purple color. When cells are proliferating, the 
dye accumulates. Cell viability is determined by measuring the absorbance at a 
certain wavelength. MTS and WST assays use alternative dyes to the MTT Assays. 
In this thesis, two cell proliferation assay kits were used. In PAPER IV, we 
detected the effect of EGFR inhibitor and MET inhibitor on cell proliferation of 
NSCLC cell lines A549, HCC827 and H1993. We used the CellTiter 96® AQueous 
Non-Radioactive Cell Proliferation Assay kit, which is based on MTS and an 
electron mediator reagent. The electron mediator reagent together with MTS yields 
a stable solution. In PAPER V, we determined the effect of hERβ2 on cell 
proliferation in a TNBC cell line BT549. We used the WST-1 kit, which contains 
water-soluble tetrazolium salts combined with electron coupling to form a water-
soluble formazan. The insoluble formazan accumulated outside cells, which 
decreases the toxicity to cells. 
 
 
 Cell invasiveness  3.8
 
The ability of cancer cells to invade is directly correlated with tumor metastatic 
potential. The BD BioCoat™ Matrigel Invasion Chamber is a low throughput, 
efficient quantitative measurement for evaluating invasion of tumor cells. In this 
thesis, BD BioCoat™ Growth Factor Reduced Matrigel™ Invasion Chambers were 
used. 2.5 × 104 cells were seeded in the upper chamber with 0% FBS media and 
complete media containing 10% FBS was added to the lower chamber. After 24  h, 
cells in the upper chamber were removed by scraping. Cells that migrated to the 
lower chamber were stained and counted.  
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 RESULTS AND DISCUSSION 4
 
 
 PAPER I 4.1
 
HUMAN ESTROGEN RECEPTOR BETA 548 IS NOT A COMMON VARIANT IN 
THREE DISTINCT POPULATIONS  
 
This study concluded for the first time that hERβ548 is not a common variant in 
Africans, Caucasians, or Asians. 
 
Several isoforms of ERβ have been reported, including variants with different N-
terminal ends. In rodents, two in-frame initiation codons (ATGs) are used to 
produce proteins of 530 and 549 amino acids, respectively. In humans, the upstream 
ATG was out of frame in all clones reported, until human clones with an extra A-T 
base pair placing an upstream ATG in frame with the rest of the coding sequence 
were reported. The authors suggested that this could represent a novel 
polymorphism in the ERβ gene. Because the suggested longer human ERβ548 
(hERβ548) and the previously identified hERβ530 display different functional 
characteristics in vitro, it is of interest to determine if this variant constitutes a 
polymorphism in human populations.  
 
We determined the frequency of this novel isoform in several populations including 
African (n = 96), Caucasian (n = 100), and Asian (n = 128) subjects using 
denaturing HPLC. We did not detect any alleles that correspond to hERβ548 in 
these samples or in additional samples of heterogeneous origin.  
 
We concluded that hERβ548 is not a common variant in Africans, Caucasians, or 
Asians. 
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 PAPER II 4.2
 
IDENTIFICATION OF A FUNCTIONAL VARIANT OF ESTROGEN RECEOTOR 
BETA IN AN AFRICAN POPULATION 
 
The aim of this study was to identify and characterize ERβ variants in an African 
America population. 
 
We identified five novel polymorphisms in the ERβ gene in an African population. 
Two of these variants I3V and V320G are expected to change the amino acid 
sequence of the ERβ protein. The I3V mutation displayed no differences with 
regard to transcriptional activity in a reporter assay, as compared with the wild-type 
receptor. The V320G mutation, however, showed significantly decreased maximal 
transcriptional activity in a reporter assay, although its binding affinity for E2 was 
not affected. A pull-down assay indicated that the interaction of full-length TIF2 
with hERβV320G was weaker than with hERβwt. Moreover, surface plasmon 
resonance analysis revealed reduced interaction of the hERβV320G variant with the 
NR box I and II modules of TIF2. 
 
These results indicate that the decreased transcriptional activity of the novel ERβ 
variant, hERβV320G, is due to the weaker interaction with a co-factor TIF2. This 
novel polymorphism could provide a tool for human genetic studies of diseases in 
the African population. 
 
 
 PAPER III 4.3
 
MOUSE ESTROGEN RECEPTOR BETA ISOFORMS EXHIBIT DIFFERENCES IN 
LIGAND SELECTIVITY AND COACTIVATOR RECRUITMENT 
 
Mouse ERβ1 (mERβ1) corresponds to the wild-type mERβ while the mouse ERβ2 
(mERβ2) is an alternative splice variant with 18 amino acid insertions in the LBD. 
In this study, we have assayed the interaction of several known ligands with mouse 
ERβ1 and mouse ERβ2 for the first time.  
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Our studies showed that mERβ1 and mERβ2 display differences with regard to 
ligand binding. The binding affinity of E2 was mERβ1 selective (14-fold) while 
binding affinity of raloxifene was mERβ2 selective (8-fold). In order to reach 
maximal transcriptional activation, mERβ2 required 10-fold greater E2 
concentrations compared to mERβ1, whereas raloxifene was more potent in 
antagonizing E2-induced gene expression via mERβ2 than mERβ1. Furthermore, 
mERβ2 showed significantly decreased E2-induced maximal transcriptional activity 
as compared to mERβ1. A pull-down assay and surface plasmon resonance analysis 
indicate that decreased E2-induced transcriptional activity of mERβ2 is associated 
with reduced interaction with both TIF2 and RAP250 co-activators compared to 
mERβ1.  
 
These results suggest that ligand selectivity and co-activator recruitment of ERβ 
isoforms constitute additional levels of specificity that influence the transcriptional 
response in estrogen target cells in mouse. 
 
When novel SERMs are tested in animal studies, the isoform dependent ligand 
selectivity in animals needs to be considered.  
 
 
 PAPER IV 4.4
 
EPIDERMAL GROWTH FACTOR RECEPTOR REGULATES MET LEVELS AND 
INVASIVENESS THROUGH HYPOXIA-INDUCIBLE FACOTR-1ALPHA IN NON-
SMALL CELL LUNG CANCER CELLS 
 
NSCLC is the leading cause of cancer-related mortality in the United States. The 
five-year survival rate can be lower than 2% for patients with distant stage. EGFR  
plays an important role in cell survival, cell proliferation, invasion and angiogenesis 
in NSCLC. A subtype of NSCLC patients carrying mutations in the EGFR tyrosine 
kinase domain, which make the EGFR auto activated and sensitive to EGFR TKIs. 
EGFR-activating mutations become a predictor marker of clinical response to 
EGFR TKIs. The aim of this study was to identify the signaling pathway involved 
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in the invasiveness of NSCLC.  
 
In this study, we analyzed 202 clinical patient specimens, different NSCLC cell 
lines and transgenic mouse models to investigate the EGFR signaling pathway in 
relation to tumorigenesis of NSCLC. Our results showed that EGFR-activating 
mutations are associated with elevated HIF-1α and MET levels in NSCLC cell 
lines. An activated EGFR pathway or hypoxia can promote cell invasion, which is 
associated with the increased expression of p-MET, MET, and HIF-1α. The 
invasiveness is MET dependent, and could be diminished by MET inhibitors or 
siRNA. These findings establish that, in the absence of MET amplification, EGFR 
signaling can regulate MET levels through HIF-1α and that MET is a key 
downstream mediator of EGFR-induced invasiveness in EGFR-dependent NSCLC 
cells. 
 
Our results indicated that EGFR- and/or hypoxia-induced tumorigenic effects in 
NSCLC are mediated through promoting cell invasion, which can be regulated via 
HIF-1α/MET axis. MET is the key downstream mediator of cell invasion in NSCLC 
cells. HIF-1α/MET axis involved in both EGFR and hypoxia induced signaling 
pathways suggests that there might be an overlap in the mechanisms that EGFR and 
hypoxia promote malignant feature and therapeutic resistance.  
 
Targeting of the MET pathway together with EGFR pathway may further block the 
tumor invasion beyond the effect of EGFR inhibition alone, may also prevent the 
possible resistance through MET amplification.  
 
 
 PAPER V  4.5
 
ESTROGEN RECEPTOR BETA1 INDUCES PROLIFERATION AND INVASION 
OF BREAST CANCER CELLS; ASSOCIATION WITH REGULATION OF PROLYL 
HYDROXYLASE 3, HYPOXIA INDUCED FACTOR 1 ALPHA AND MET 
 
Many studies indicated that ERβ variant hERβ2 is expressed at higher levels than 
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hERβ1 in breast cancer and that hERβ2 expression is associated with aggressive 
phenotypes in various cancers. We determine the phenotypes and molecular 
mechanisms of hERβ2, independent of ERα and hERβ1, in breast cancer cells. 
 
The TNBC cell line BT549 was used as model system. hERβ2 levels were 
modulated by transient overexpression or knockdown by siRNAs. Cell proliferation 
and invasion were assayed by the WST-1 cell proliferation assay kit and growth 
factor reduced BD MatrigelTM invasion chamber, respectively. GeneChip® Human 
Gene 1.1 ST Affymetrix microarrays were used to assay global gene expression. 
hERβ2 regulation of mRNA and protein levels of selected genes was investigated 
by qPCR and western blot analysis, respectively.  
 
In this study we show that hERβ2 is the dominant ER isoform in the BT549 cell 
line and promotes proliferation and invasion of this cell line. A total of 263 genes 
were identified as hERβ2-upregulated genes and 662 identified as hERβ2-
downregulated genes. hERβ2-regulated genes were involved in cell morphology, 
DNA replication and repair, cell death and survival. We show that hERβ2 represses 
PHD3 gene expression and induces protein levels of HIF-1α and MET.  
 
We concluded that hERβ2 promotes cell proliferation and invasion of BT549 breast 
cancer cells. The invasive phenotype could potentially be mediated through 
transcriptional repression of PHD3, followed by up-regulation of the HIF1α-MET 
pathway. 
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 GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES  5	  	  
 
 ERβ SNPs in African Americans and disease susceptibility  5.1
 
Compared to white Americans, African-Americans have poor outcome of certain 
diseases such as breast cancer and prostate cancer. The mortality rate of breast 
cancer is three times higher in African American than other populations. Notably, 
the prevalence of TNBC is highest in premenopausal African American women 
[145]. It was reported that 39% of premenopausal African American breast cancer 
patients was diagnosed with TNBC [146]. The prevalence of TNBC among non-
African American is around 15% and the difference was not seen in other breast 
cancer subtype groups [146]. We speculate that African-specific genetic variants 
may be associated with the susceptibility to specific subtypes of cancer. One recent 
report found that the SNP rs10069690 in the TERT gene was significantly 
associated with TNBC in an African ancestry population [147]. We are one of the 
very few groups studying polymorphisms of ERβ genes in African populations. We 
screened the ERβ gene in an African population for polymorphisms. The identified 
polymorphism, particularly a functional polymorphism, would constitute important 
tools for further disease association studies in this population. Future studies should 
address the frequency of the two identified polymorphisms that change the amino 
acid sequence of the ERβ protein in a much larger cohort. It would also be 
interesting to investigate if these SNPs are present, and their frequency, in other 
populations. Finally, further functional studies of these variants could involve 
generating mice strains with the corresponding SNPs in ERβ. 
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 Rodent ERβ2; considerations when performing animal studies using ER 5.2
agonists and antagonists 
	  
Our studies showed that the binding affinity of E2 was mERβ1 selective while 
raloxifene was mERβ2 selective. mERβ2 required 10-fold greater E2 concentrations 
compared to mERβ1 to reach the maximal transactivity, whereas raloxifene was 
more potent in antagonizing E2-induced gene expression via mERβ2 than mERβ1.  
 
Mouse and rat are commonly used animal models to study ER function in vivo. 
Furthermore, disease models in mouse and rat are used to evaluate the effect of 
compounds with estrogenic or anti-estrogenic properties to improve the disease 
condition. As humans do not have mERβ2, this isoform-dependent ligand 
selectivity, reported for the two rodent ERβs in this study, needs to be considered 
when novel compounds are tested in animal studies. A further complication arises 
from the fact that the relative levels of mERβ1 and mERβ2 likely vary between 
tissues. The development of mice strains lacking expression of mERβ2 would be an 
important development. However, humanized mice, in which the mouse ERβ LBD 
was replaced by human ERβ LBD showed embryo lethality (Per Antonson, personal 
communication).   
 
 
 Estrogen signaling, cell proliferation and invasion 5.3	  
Estrogens promotes epithelial cell proliferation in both normal and neoplastic breast 
[148] and ER signaling is associated with tumorigenesis, metastasis and therapeutic 
resistance.  
 
In our study we showed that hERβ2 is the predominant endogenously expressed ER 
in a TNBC cell line BT549 and promotes cell proliferation and invasion in this cell 
line. We demonstrate that the invasive phenotype associated with hERβ2 expression 
could potentially be via repressing expression of PHD3 followed by up-regulation 
of the HIF-1α-MET pathway or direct regulation of MET.  
EGFR and HIF-1α-MET signalling pathways are known to play important roles in 
tumorigenesis and therapeutic resistance. Recently PHD3 has been shown to exert 
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tumor-protective functions and to inhibit tumor growth in pancreatic cancer. Our 
study contributes to the understanding of the molecular mechanism of hERβ2 
regulation of cell proliferation and invasion. Future studies should focus on how 
hERβ2 regulates PHD3 and ultimately cell proliferation and invasion. It will be 
important to identify additional cell lines expressing hERβ2 in the absence of other 
ERs to investigate the generality of the observations, both TNBC cell lines and cell 
lines of different origin, including regulation of PHD3 and the HIF-1a-MET 
pathway. Furthermore, it will be important to pursue similar studies in cell lines 
expressing hERβ2 in the presence of ERα and/or hERβ1. The correlation of hERβ2 
with PHD3 or components of the HIF-1α-MET pathway in clinical samples will 
provide evidence for the clinical relevance of our findings. Although, in this thesis, 
we focus on hERβ2 regulation of PHD3 and the HIF-1α-MET pathway, other 
potential mechanisms should be explored. These could be derived from a more 
careful examination of the global gene expression profiling data already obtained. 
Furthermore, the global gene expression profiling data is derived from a single time 
point following inhibition of hERβ2 with siRNA. Performing global gene 
expression profiling at additional time points following siRNA transfection might 
reveal alternative potential targets responsible for the observed phenotypes. Such 
studies could also include identification hERβ2 regulated miRNAs and other non-
coding RNAs. Finally, although hERβ2 does not bind tested ER ligands, it is 
possible that compounds that inhibit its function or target genes can be identified, 
thus providing potential therapeutic agents for breast cancers that express hERβ2.   
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Human Estrogen Receptor  548 Is Not a Common
Variant in Three Distinct Populations
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Several isoforms of estrogen receptor (ER)  (also known as
NR3A2) have been reported, including variants with different
N-terminal ends. In rodents, two in-frame initiation codons
(ATGs) are used to produce proteins of 530 and 549 amino
acids, respectively. In humans, the upstream ATG is out of
frame in all clones reported, until recently, when human
clones with an extra A-T base pair placing the upstream ATG
in frame were reported. The authors suggested that this could
represent a novel polymorphism in the ER gene. Because
human ER548 (hER548) and hER530 display different
functional characteristics in vitro, it is of interest to deter-
mine if this variant constitutes a polymorphism in human
populations. We therefore determined the frequency of this
novel isoform in several populations including African (n 
96), Caucasian (n  100), and Asian (n  128) subjects using
denaturing HPLC. We did not detect any alleles that corre-
spond to hER548 in these samples or in additional samples
of heterogeneous origin. It is concluded that hER548 is not
a common variant in Africans, Caucasians, or Asians. (Endo-
crinology 144: 3541–3546, 2003)
MOST OF THE effects of estrogen are mediated by es-trogen receptors (ERs). ERs belong to the steroid
hormone receptor gene superfamily of ligand-activated tran-
scription factors.
For many years, one ER was thought to mediate all cellular
effects of estrogen. This receptor is now referred to as ER
(NR3A1). However, in 1995 another ER, named ER
(NR3A2), was cloned from rat prostate (1). Several isoforms
of ER have subsequently been reported, including variants
with differing N-terminal ends. The ER gene cloned from
rat prostate (1) encodes a protein of 485 amino acids. Three
years later, a rat prostate ER cDNA sequence was submitted
to GenBank, which differs from the initial sequence by the
addition of one nucleotide upstream of the start codon. The
extra nucleotide removes the in-frame stop codon upstream
of the start codon initially reported (1), resulting in a cDNA
that encodes 64 additional amino acids at the N terminus (2).
This form is now referred to as rER549 and is considered to
be the long form or full-length rodent ER.
The first human ER (hER) cloned encompassed 477
amino acids (3). The N terminus of hER has since then been
extended. Ogawa et al. (4) cloned a longer hER that has been
considered as the full-length ER, consisting of 530 amino
acids, hER530. There is an initiation codon (ATG) at a sim-
ilar position in human clones as that encoding the full-length
rodent rER549 (Fig. 1, A and B). However, in all human
clones originally reported, this ATG is out of frame with the
rest of the coding sequence.
Recently, an N-terminally extended hER variant, corre-
sponding to hER548, was cloned from human testis cDNA
and genomic DNA (5). An additional A-T base pair shifts the
out of frame ATG to be in frame (Fig 1C). In the following,
the allele representing the extra A-T base pair and expected
to encode hER548, is referred to as the A allele. Interest-
ingly, hER548 appears more robust than hER530 with
regard to transcriptional activation via an estrogen response
element in response to 17-estradiol. Furthermore, both ta-
moxifen and raloxifen showed significant agonist activity via
hER548, which was not observed via hER530. The authors
suggested that this extra nucleotide might represent a poly-
morphism. If this is true, it is of obvious interest to determine
the frequency of hER548 in different populations.
Materials and Methods
Samples
Blood samples were taken from blood donors for the following pop-
ulation groups: Africans (n 96, Gambian, from Banjul) and Asians (n
128 Han Chinese, from Beijing). The Caucasian samples were from
Finland (n  100, which included 50 breast cancer patients).
Information for additional samples analyzed from diverse origins is
shown in Table 1. Studies were approved by ethical committees.
PCR
Primer ER-5 untranslated region (UTR) 5: TTATACTTGCCCAC-
GAATCTTT and primer ER-5UTR3: CTTGCTTCACACCAGG-
GACTCT were used to amplify part of hER exon 1. PCR amplifications
were performed in a total volume of 25 l containing 250 m de-
oxynucleotide triphosphates, 10–50 ng of template DNA, 0.5 m each of
primers, 1.25 U AmpliTaq Gold DNA polymerase (PE Applied Biosys-
tems, Foster City, CA), in 1 reaction buffer [10 mm Tris HCl (pH 8.3);
50 mm KCl; and 2.5 mm MgCl2]. PCR amplification was carried out at
94 C for 10 min and then cycled 35 times at 94 C for 30 sec, 57 C for 30
sec and 72 C for 45 sec, followed by 10 min at 72 C.
Abbreviations: DHPLC, Denaturing HPLC; hER, human ER; UTR,
untranslated region.
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Generation of an artificial hER548 clone
A standard ER530 plasmid contains the 5UTR where the ATG
encoding hER548 is out of frame. An artificial hER548 plasmid that
has the reported extra nucleotide of the ER gene that generates
hER548 (Ref. 5; and Fig. 2B) was created from the standard hER530
plasmid using the QuikChange XL Site-Directed mutagenesis kit (Strat-
agene, La Jolla, CA). The sequences of these two clones were confirmed
by DNA sequencing. DNA fragments amplified by PCR (using the same
pair of primers as used in amplifying genomic DNA) from these plas-
mids served as controls throughout the experiments and are named
hER530st and hER548art, respectively. The sequences of these PCR
products were confirmed by DNA sequencing.
Denaturing HPLC (DHPLC)
Samples were denatured at 95 C and then cooled to 25 C over 45 min
to enable the formation of heteroduplexes. Samples were analyzed with
DHPLC using a Wave Fragment Analysis System (Transgenomics,
Omaha, NE) and DNASep Column as described (6) using the suggested
temperature 58 C.
Results
Generation of an artificial clone encoding hER548
hER530 has been considered to be the full-length hER.
The sequences of the N-terminal region of the hER gene
including that generating the recently reported hER548 are
shown in Fig. 1. The sequence of a plasmid encoding
hER530 is shown in Fig. 2A. This plasmid and subsequent
PCR products generated from it are referred to as hER530st.
An artificial plasmid encoding hER548 was generated in-
cluding the extra A-T base pair as reported (5). This plasmid
and subsequent PCR products generated from it are referred
to as hER548art.
FIG. 1. Nucleotide and deduced amino acid sequences of the N-terminal region of hER. The amino acids sequence is given in the one letter
code. A, The sequence that encodes hER530. The upstream ATG is out of frame with the rest of the coding region. The GenBank accession
no. is AB006590. B, The sequence that encodes full-length mouse ER549. The additional 19 amino acids that are specific to mER549 are
underlined. The GenBank accession no. is AF067422. C, The sequence that encodes hER548. The extra A that places the upstream ATG in
frame with the rest of the coding sequence is marked by *. The additional 18 amino acids that are specific to hER548 are underlined. The
GenBank accession no. is AX029400.
TABLE 1. Wave Fragment Analysis System analysis of diverse-
origin samples that were negative for hER548
Genomic DNA Number of chromosomes
analyzed (2n)
Diverse geographical samplesa
Mixed European descent 88
Near East and North Africa 94
Caucasian subjects with
female infertility
130
cDNA Number of samples
analyzed (n)
English subjects with breast
cancer
6
Human testis Marathon-ready
cDNA (CLONTECH)
1
a DNA samples of European, Near-Eastern, and North-African
origin, representing a variety of regions and populations, were ob-
tained on nonnominative basis from consenting adults providing in-
formation about their ethnic, linguistic, and geographic origins or
were purchased from Coriell Institute for Medical Research (Cam-
den, NJ).
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Validation of DHPLC for detection of the A allele
DHPLC is based on the differential adsorption of homo-
and hetero-duplexes to a hydrophobic matrix on a chro-
matographic column. Amplified products with a mismatch
will form hetero-duplexes that have decreased interaction
with the matrix and will be eluted earlier than the normal
homo-duplexes. Figure 3 shows that the A allele can be
detected with DHPLC using the employed conditions. To
detect possible homozygotes for theA allele, PCR products
from analyzed individuals were mixed with the hER530st.
To detect heterozygotes for the A allele, samples were
analyzed without mixing. The sensitivity of DHPLC in de-
tecting the presence of an extra nucleotide was evaluated
with PCR fragments derived from hER 530st and hER
548art, respectively. When the amounts of hER530st and
hER548art differ less than 10-fold, the A allele can be
detected (Fig. 3). This shows that it is not absolutely critical
for the analysis that the amounts of target and hER530st
PCR products, respectively, are identical.
Screening of genomic DNA from different populations
In total, 96, 100, and 128 DNA samples from African,
Caucasian, and Asian subjects, respectively, were screened
by DHPLC. Figure 4A shows, from the top, representative
DHPLC profiles obtained from analysis of genomic DNA
from Caucasian (n  100), African (n  96), and Asian (n 
128) populations, analyzed after mixing with hER530st.
Similar profiles were obtained when samples were analyzed
without prior mixing with hER530st. No heteroduplex
peak, indicative of the presence of hER548art, could be
identified in any of the samples. The presence of hER548
would have been seen as a heterduplex as shown in Fig. 4B
where the samples were mixed with hER548art. This figure
also shows that the hER530 variant can be detected in these
samples.
In addition, we have also screened a number of additional
samples for the hER548 variant. These data are summarized
in Table 1. We have analyzed genomic DNA from individ-
uals from a very diverse geographical sampling and from
individuals with syndromes related to infertility. cDNA has
been analyzed from breast cancer patients and from a com-
mercial source. We did not identify hER548 in these
samples.
From these results, we conclude that the human 548-
amino-acid ER does not represent a common allele.
Discussion
Knowing that a single gene might generate several protein
products, researchers need to address an additional level of
complexity in understanding the function of any gene and its
encoded protein product. The ER gene is an example of a
gene from which several protein products are derived. This
occurs through alternative RNA splicing (7–19) or through
the utilization of different translation start codons in the 5
flanking region, generating several N-terminally variable
ER proteins. In this report, we focus on the frequency of the
recently reported hER 548 isoform (5). We developed a
DHPLC assay for screening of theA allele and showed that
it was robust with regard to detection of samples heterozy-
FIG. 2. DNA sequence flanking the artificial extra A nu-
cleotide producing the  A allele. A, Sequence of
hER530st. B, Sequence of hER548art, which was cre-
ated by mutagenesis. The artificially inserted A (boxed) is
indicated by an arrow.
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gous and homozygous for the A allele. This report focuses
on the screening of samples from 128 Asian, 96 African, and
100 Caucasian individuals for the A allele encoding hER
548. Notably and surprisingly, we did not identify any single
allele corresponding to the A allele. Moreover, analysis of
further samples of different origin did not reveal a single 
A allele. The reason why we did not detect hER548 in
human testis Marathon-ready cDNA (CLONTECH Labora-
tories, Inc., Palo Alto, CA), where it was identified in Ref. 5,
is presently unclear. The lot number is not indicated in Ref.
5. Without knowledge about the lot number, CLONTECH
Laboratories, Inc. cannot track if the lots are derived from
FIG. 3. DHPLC profiles obtained from a wide range of ratios between ER530st and ER548art. When the ratio is no less than 1:10, the
heteroduplex peak could be detected.
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identical RNA sources (information from CLONTECH Lab-
oratories, Inc.).
In this paper, we demonstrate that a potential polymorphic
ER variant encoding hER548 is, if it at all exists, a rare
variant in African, Caucasian, and Asian populations. How-
ever, there is still the interesting possibility that this allele
could exist in special populations and/or that it could be
specifically associated with certain syndromes.
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In this study, we identified five novel polymorphisms in the
estrogen receptor beta (ERb) gene in an African popula-
tion. Interestingly, two of these variants are expected to
change the amino acid sequence of the ERb protein. These
changes correspond to an isoleucine to valine substitution
at amino acid position 3 (I3V) and a valine to glycine sub-
stitution at position 320 (V320G), respectively. The func-
tional consequences of these amino acid substitutions were
determined in different in vitro assays. The I3V mutation
displayed no differences with regard to transcriptional
activity in a reporter assay, as compared with the wild-
type receptor. The V320G mutation, however, showed sig-
nificantly decreased maximal transcriptional activity in
a reporter assay, although its binding affinity for 17b-
estradiol was not affected. A pull-down assay indicated
that the interaction of full-length TIF2 with hERbV320G
was weaker than with hERbwt. Moreover, surface plas-
mon resonance analysis revealed reduced interaction of the
V320G ERb variant with the NR box I and II modules of
TIF2. To our knowledge, this represents the first identi-
fication of a functional polymorphism in the ERb gene.
This novel polymorphism provides a tool for human
genetic studies of diseases in the African population.
Introduction
Estrogen receptors (ERs) belong to the steroid/retinoid
receptor gene superfamily, which contains the receptors for
glucocorticoids, mineralocorticoids, progesterone, androgen,
thyroid hormone, vitamin D and retinoic acid. As a family,
its members share some structural and functional similarities
including four functional domains. From the N-terminus to the
C-terminus of the receptor molecule, these are: the A/B region
that contributes to the transcriptional activation function; the
C-region, or the DNA-binding domain, that harbors the DNA-
binding function mediating specific DNA binding; the hinge
region followed by the ligand-binding domain (the LBD or the
E/F domain). The LBD harbors the ligand-binding pocket as
well as sites for co-factor binding, transactivation, nuclear
localization and interactions with heat shock proteins (1).
Upon ligand-dependent or -independent activation, these
receptors form dimers and modulate transcription by binding
to their corresponding hormone response elements (for example
ERE, estrogen response element) in the promoter region of
target genes (2). There are two estrogen receptors, ERa and
ERb. These two receptors show high homology, particularly in
the DNA-binding domain. The receptors are expressed in a
distinct but sometimes over-lapping mode and display func-
tional similarities as well as differences, sometimes even
opposite actions (3).
Polymorphisms in ER genes, the major mediators of estro-
gen signaling, are associated with some endocrine related
disorders. Polymorphisms in ERa are associated with breast
cancer (4--6), endometrial cancer (7), lupus nephritis (8), men-
strual disorder (9), Alzheimer’s disease (10), osteoporosis (11)
and coronary artery disease (12). Polymorphisms in the ERb
gene have been correlated to other pathological states as com-
pared with ERa polymorphisms, such as ovulatory dysfunc-
tions (9), hypertension (13), bone mineral density (14) and
androgen levels (15). No data are available regarding poly-
morphisms in ER genes in African populations.
Several genetic differences have been described between
African Americans and white Americans, which may account
for the higher incidence of certain diseases in the former popu-
lation. For example, estrogen metabolism appears to vary
according to race, with a higher ratio of inactive:active meta-
bolites in whites compared with blacks (16). Polymorphisms in
some steroid hormone nuclear receptors have been shown to
correlate with race related endocrine diseases. For example,
short CAG repeat lengths in the androgen receptor gene were
found in African Americans and possibly associated with a
higher stage of prostate cancer (17). Polymorphisms in the
vitamin D receptor gene are associated with bone mass differ-
ences between African Americans and white Americans (18).
In this investigation we screened the ERb gene in an African
population for polymorphisms. Any identified polymorphism,
particularly a functional polymorphism, would constitute
important tools for further association with diseases.
Materials and methods
Samples
Nigerian healthy blood donors (n ¼ 96 from Banjul, Gambian) were included
in the study. Genomic DNA was isolated using standard phenol--chloroform
extraction followed by ethanol precipitation. The studies were approved by the
ethical committee of the Karolinska Institute.
PCR
PCR amplifications were performed in a total volume of 25 ml containing
200 mM dNTPs, 10--50 ng of template DNA, 0.4 mM each of primers, 1.25 U
Taq DNA polymerase (Roche, Mannheim, Germany), in 1 reaction buffer
(10 mM Tris--HCl pH 8.3, 50 mM KCl, 2.5 mM MgCl2). Primer sequences to
amplify the ERb gene were designed based on the published GenBank ERb
gene sequence NT_025892 (Table I). PCR amplification was carried out at
94C for 10 min followed by 35 cycles (94C for 30 s, 57--60C for 30 s and
72C for 45 s), and finally 10 min at 72C.
Abbreviations: ER, estrogen receptor; ERE, estrogen response element;
LBD, ligand-binding domain; SPR, surface plasmon resonance.
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Denaturing high-performance liquid chromatography (DHPLC)
PCR products from amplification of genomic DNA from all individuals were
analysed using DHPLC on a WAVE DNA Fragment Analysis System (Trans-
genomic, Cheshire, UK) and DNASep Column as described (19) using the
temperature suggested by the WAVEMAKERTM Software package (Trans-
genomic, Crewe, UK). Prior to DHPLC analysis, PCR products were denatured
at 95C for 5 min and then cooled to 25C over 45 min to enable the formation
of heteroduplexes. Aliquots of 5 ml were automatically loaded on the DNAsep
column for heteroduplex analysis.
Samples with aberrant HPLC profiles were subjected to DNA sequencing
using ABI Prism BigDyeTM Terminator Cycle Sequence Ready Reaction Kit
(Applied Biosystems) and compared with the publishedgenomic sequence of the
ERb gene. In certain cases, Restriction Fragment Length Polymorphism ana-
lysis was used to confirm polymorphisms. FokI was used to score 105A!G,
RsaI was used to score 1082G!A, AluI was used to score1730G!A and
Van91I was used to score 1057T!G.
Generation of human ERb plasmids containing the 105A!G or 1057T!G
mutations
A wild-type pSG5-hERb plasmid was a gift from Dr Michel Tujague at the
Department of Biosciences, Karolinska Institute. hERb plasmids that incorp-
orate the identified amino acid changes of the ERb gene were created from the
wild-type hERb530 plasmid using the QuickChangeTM XL Site-Directed
mutagenesis kit (Stratagene, La Jolla, CA) according to the instruction manual.
DNA sequencing confirmed the sequences of the mutant clones. The resulting
plasmids are named hERb105A!G and hERb1057T!G, respectively.
Transient transfection assays and western blot analysis
HEK293 cells were cultured in a 1:1 mixture of Ham’s Nutrient mixture
F12 (Invitrogen) and DMEM (Invitrogen) supplemented with 5% FBS and
100 U penicillin/ml and 100 mg streptomycin/ml. For transfection, the cells
were seeded at a density of 1  104 cells/well in 96-well plates and
co-transfected with 2 ERE TK luciferase reporter plasmid (0.4 mg) (20)
and the respective ER expression vectors (0.016 mg). A pRL-TK control
plasmid, which contains a Renilla luciferase gene, was included to control for
differences in transfection efficiencies. The medium was replaced with a phenol
red-free mixture of F12 and DMEM containing 5% dextran-coated charcoal-
treated FBS and 100 U penicillin/ml and 100 mg streptomycin/ml upon trans-
fection. 17b-Estradiol (0.1, 1, 10, 100 nM) or vehicle (in 0.1% ethanol) was
added just after transfection. The cells were harvested 24 h after transfection
and luciferase activities were determined using the Dual Luciferase Reporter
Assay System (Promega) according to the manufacturer’s instructions.
Western blotting was done according to the protocol as described (21). ERb
was detected with an ERb LBD rabbit polyclonal antibody produced by us
as described previously (22). As a positive control, the recombinant human
ERb530 protein purchased from Panvera (Madison, WI) was used.
Cloning and expression of hERbwt and hERb1057T!G LBDs
The LBDs (R254 to Q530) were obtained by PCR using full-length cDNAs as
templates and primers that contained appropriate restriction sites. hERbwt and
hERb1057T!G were cloned into pET15b (Novagen, Madison, WI) to gen-
erate proteins with N-terminal His-tags. The sequences of all constructs were
verified by DNA sequencing.
Cultures (500 ml) of the Escherichia coli strain BL21, transformed with the
appropriate expression plasmids, were cultivated overnight in LB supplemen-
ted with 100 mg/ml of ampicillin at 37C. When the OD600 reached 1.0,
IPTG was added to a final concentration of 1 mM and incubation continued
for 3 h at 25C. The cells were pelleted and the supernatant was discarded. The
pellet was suspended in 5 ml (one-tenth of the culture volume) of extraction
buffer [complete EDTA-free, Roche Diagnostics, Germany, 0.3 M NaCl,
20 mM Tris (pH 8.0), 0.01 mg/ml DNase, 0.01 mg/ml RNase, 10 mM
MgCl2, 0.25 mg/ml lysozyme, 1 mM b-ME and protease inhibitor cocktail
tablet]. The samples were sonicated for 4 min at 50% duty (total sonication
time 2 min). The homogenate was centrifuged at 13 000 g for 20 min at 4C.
The supernatant was applied to a TALON metal affinity column (Clontech
Laboratories, Palo Alto, CA). Fractions containing the purified protein were
dialyzed against 20 mM Tris (pH 8), 150 mM NaCl, 1 mM DTT and frozen at
80C. The purified protein was495% pure as determined from Coomassie
stained SDS--PAGE gels. The protein concentrations were measured using the
Coomassie Protein Assay Kit (Pierce, IL) according to the manufacturer’s
instructions.
Scintillation proximity assay
The assay was performed in 96-well microplates (PerkinElmer Life Sciences,
MA). Polyvinyltoluene copper-loaded his-tag beads were purchased from
Amersham. The reaction mixture (60 ml/well) containing assay buffer (1 mM
EDTA, 0.9 M KH2PO4, 0.1 M K2HPO4, 20 mM Na2MoO4 and 0.05% mono-
thioglycerol), beads (30 mg/well) and purified ERb LBD (final concentration
of 20 nM) was incubated at 4C for at least 1 h. For saturation ligand-binding
analysis, a sample of various concentrations of [3H]17b-estradiol (S.A. ¼
95 Ci/mmol) in the presence or absence of a 300-fold excess of unlabeled
17b-estradiol was then added. The assay plates were sealed, allowed to settle
overnight and subsequently counted on a Wallac 1450 micro-b counter. The
dissociation constant (Kd) was calculated as the free concentration of radio-
ligand at half-maximal specific binding by fitting data to the Hill equation and
by linear Scatchard transformation (23). Curve fitting was done in Prism
(GraphPad Software).
For ligand competition studies, purified ERb LBDs (20 nM) were incubated
overnight at 4C with a range of test compound concentrations. A final
concentration of 1.5 nM [3H]17b-estradiol (30 ml/well) was used. The ligands
were tested three times with similar results. Curve fitting was performed using
Prism (GraphPad Software) and the IC50s determined. IC50 values were con-
verted to Ki using the Cheng-Prusoff equation, Ki ¼ IC50/(1þ D/Kd), where D
is the concentration of the radioligand (24).
Pull-down assay
For pull-down assays, purified His-tagged ERb LBDs (100 mg) were bound to
60ml of Talon resin and then equilibrated in 50 mM Tris--HCl, pH 7.4, 100 mM
NaCl, 1 mM MgCl2, 10% glycerol and 0.5% NP-40 (equilibration buffer). The
gel slurry was then divided into two equal aliquots and to each tube, 2.5 ml
of in vitro translated, 35S-labeled (TNT coupled reticulocyte lysate system,
Promega), full-length TIF2 was added in a total volume of 150 ml equilibration
buffer containing 1.5% BSA. Estradiol or vehicle (ethanol) was added as
indicated. As control, TIF2 was mixed with Talon gel without bound ERb.
All samples were incubated for 2 h with gentle shaking at 4C. After washing
three times with equilibration buffer, bound proteins were eluted with
SDS--PAGE sample buffer and separated on a 12% polyacrylamide gel. The
gel was stained with Coomassie Blue, followed by determination of 35S using a
PhosphoImager instrument.
Surface plasmon resonance (SPR) analysis
All SPR measurements were performed on a BIAcore 2000 instrument (BIA-
core AB, Uppsala, Sweden). All experiments were performed at 25C, and at a
flow rate of 5 ml/min. Research grade streptavidin sensor chips were obtained
from BIAcore AB. The streptavidin chips were first treated with three 1-min
pulses of 50 mM NaOH and 1 M NaCl at a flow rate of 5 ml/min. N-terminally
biotinylated peptides (495% purity) were purchased from Interactiva
(Germany). The human TIF2 LXXLL peptide sequences were as follows:
Box 1 (residues 636--649), KGQTKLLQLLTTKS and Box 2 (residues
685--698), EKHKILHRLLQDSS. Peptides were immobilized on individual
surfaces to 200 RU responses. Samples of purified hERbwt-LBD or
hERbV320G-LBD in the presence or absence of estradiol were then injected
over each surface. After injection stop, the surfaces were washed with buffer to
monitor the dissociation phase. The buffer used was 50 mM Tris--HCl, pH 7.4,
Table I. Primers for PCR amplification of the ERb gene fragments
Exon Primer sequences Product
size
50 UTR Forward 50 TTATACTTGCCCACGAATCTTT 30 419 bp
Reverse 50 CTTGCTTCACACCAGGGACTCT 30
1 Forward 50 CTTAATTCTCCTTCCTCCTAC 30 387 bp
Reverse 50 GTGATTTGAGAAATGGCTAGC 30
2 Forward 50 GCTTTGCTGTATCAGATTTCCGGG 30 407 bp
Reverse 50 ATTTCTGCCAAGTCATCTCTGC 30
3 Forward 50 TGGCTTTGTACCTGTACTGGTCAT 30 473 bp
Reverse 50 GCCAAAATCTGCCTCCCATAATC 30
4 Forward 50 GTCGTTGGTTTTGCTAGTACGG 30 567 bp
Reverse 50 CCAGCTGAGGACCTGTTAAATA-
TCTAGGC 30
5 Forward 50 GTTGCGCAGCTTAACTTCAAAGT-
TTTCTTC 30
456 bp
Reverse 50 TGAAGGAGCTGATGCTATCATC 30
6 Forward 50 GTTTCCTGAAGCTATGTTCCT 30 242 bp
Reverse 50 CGCTAGTTGTAGAAACAGCAT 30
7 Forward 50 TGCATTAGGCCAGGCTTCTCTTCT 30 562 bp
Reverse 50 GTGCCCATCTTTGCTTACAGGTG 30
8 Forward 50 GTAGACTGGCTCTGAGCAAAGA-
GAGCC 30
405 bp
Reverse 50 CCAAGCCTGCCATCACCAAATGAG 30
cx Forward 50 GAGCAAACCAGCTTAAAGGCCC 30 473 bp
Reverse 50 CTCATGGGTGAGACATCTGCAAGC 30
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150 mM NaCl, 1 mM EDTA, 0.05% Tween 20. For the kinetic measurements,
various concentrations of hERbwt-LBD and hERbV320G-LBD (from 0.25 to
2 mM) were injected over the chip surfaces. The BIAevaluation software
version 3.1 was used for evaluation. Different binding models (different rate
equations) were tested in the global curve fitting procedure, and the model best
describing the experimental data was a 1:1 binding with drifting baseline
model. The apparent Kd values are calculated as described (25).
Results
ERb polymorphism screening in an African population
We screened genomic DNA from 96 Nigerians to identify
polymorphisms in the ERb gene in an African population.
Analysis of the coding exons and flanking intron sequences
revealed several known but also novel variants. The results are
summarized in Table II. Three variants (1082G!A, 1505-
4A!G and 1730A!G) that have been reported previously
in Caucasian populations (26,27) were also found in the
African population but with different frequencies. None of
these polymorphisms change the amino acid sequence of the
ERb protein. Five novel polymorphisms in the coding region
of the ERb gene were found in the African population.
Interestingly, as shown in Table II, two of these novel
polymorphisms change the amino acid sequence of the ERb
protein. The novel amino acid changes are 105A!G
[changing amino acid 3, isoleucine (I)!valine (V)] in exon 1
and 1057T!G [changing amino acid 320, valine (V)!glycine
(G)] in exon 5. These two ERb variants are, in the following,
referred to as hERbI3V and hERbV320G, respectively.
hERbV320G shows reduced transcriptional activation in a
transactivation assay
To test if the identified receptor variants displayed any differ-
ences compared with the wild-type receptor with regard to
transcriptional activation, a reporter assay was used. We gen-
erated plasmids expressing either hERbI3V or hERbV320G
under control of the SV40 promoter. The transcriptional activ-
ities of the variants were compared with that of the wild-type
ERb using an ERE-luciferase reporter system. No differences
with regard to transcriptional activation were observed for the
hERbI3V variant (Figure 1A). However, hERbV320G showed
significantly decreased maximal transcriptional activity com-
pared with wild-type ERb (Figure 1A). To confirm equivalent
ERb expression, extracts from HEK293 cells transfected with
equal amounts of the expression vectors for hERbwt,
hERbV320G, or hERbI3V were separated by SDS--PAGE
and analysed for ERb expression by western blot (Figure 1B).
This analysis shows that the different ERb derivatives are
expressed at similar levels. The observed reduction in maximal
transcriptional activity could imply that hERbV320G is defec-
tive for interactions with co-factors. Interestingly, as shown in
Table II. Polymorphisms in the ERb gene in an African population
Nucleotidea Amino acid Frequency
Reported (26,27) (Caucasian) African (n ¼ 96)
Heterozygotes Homozygotes Heterozygotes Homozygotes
Exon 1 105A!G 3I!V 0.052 (n ¼ 5) 0
143C!T Silent 0.042 (n ¼ 4) 0
Exon 2 566A!T Silent 0.01 (n ¼ 1) 0
Exon 5 1057T!G 320V!G 0.031 (n ¼ 3) 0
1100T!G Silent 0.01 (n ¼ 1) 0
1082G!A Silent 0.03--0.16 0.004 0.33 (n ¼ 32) 0.02 (n ¼ 2)
Exon 8- 1505-4A!G 0.06--0.16 0.004 0.32 (n ¼ 31) 0.02 (n ¼ 2)
30 UTR 1730A!G 0.43--0.52 0.11--0.13 0.25 (n ¼ 24) 0.07 (n ¼ 7)
aSee ref. (49) for numbering of genomic sequences.
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Fig. 1. hERbV320G has decreased maximal transcriptional activity
compared with hERbwt or hERbI3V. (A) Transcriptional activity of ERb
wild-type and variant proteins assayed on 2 ERE TK luciferase reporter.
HEK293 cells were transfected with the 2 ERE TK luciferase reporter
plasmid and expression plasmids encoding wild-type (^ ) or mutated-type
ERb (hERbI3V ¼ D, hERbV320G ¼), respectively. Cells were treated
with vehicle (ethanol) or indicated concentrations of 17b-estradiol. Values
represent the mean SD of three independent experiments. (B) Western blot
of identical amounts (150 mg protein) of whole cell extracts from HEK293
cells transfected with equal amounts of the expression vectors for hERbwt,
hERbV320G or hERbI3V. Recombinant human ERb530 protein was used
as positive control. The blot was stripped and probed for b-actin. The bands
were quantified by densitometric scanning and the amount of ERb
normalized to b-actin. Data are the value (in pixels) for ERb divided by the
value (in pixels) for b-actin and normalized to the hERbwt expression level,
which was set to 1. The bar graph shows the mean  SD of the three
separate experiments.
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Figure 2, the amino acid changed in hERbV320G is located
on the surface of the receptor protein, quite distant from the
ligand-binding pocket.
hERbwt and hERbV320G bind ligands with similar affinity
To facilitate a biochemical characterization of hERbV320G,
and particularly to compare it to hERbwt, the LBDs of these
two proteins were expressed in E.coli and the recombinant
proteins were purified. In Figure 3A and B, the results of
saturation ligand-binding assays with tritiated estradiol
are shown. The measured Kd values were 1.50 nM for hERbwt
wt and 1.79 nM for hERbV320G (Figure 3). Affinities for
estradiol, tamoxifen and raloxifen, as determined in a competi-
tion assay, were also similar for hERbwt and hERbV320G.
Thus, the Kis of estradiol, tamoxifen and raloxifen for hERbwt
were 0.25, 5.45 and 9.45 nM and for hERbV320G they were
0.33, 5.33 and 10.11 nM, respectively. This is consistent with
the position of the variant amino acid distant from the ligand-
binding pocket (Figure 2).
hERbV320G shows reduced co-factor interaction
Having demonstrated that hERbV320G binds ligands with
similar affinity as hERbwt, yet shows significantly reduced
maximal transactivation in a reporter assay, we hypothesized
that hERbV320G is defective for co-factor interactions. This is
consistent with the position of the V320G amino acid change,
on the surface of the receptor protein in a region postulated to
be involved in co-factor interactions (Figure 2). To test this
hypothesis, we performed pull-down assays using purified
His-tagged ERb LBDs and 35S-labeled full-length TIF2 in the
presence or absence of estradiol. As shown in Figure 4, TIF2
bound to hERbwt and hERbV320G in a ligand-dependent
manner. Furthermore, the interaction of TIF2 with
hERbV320G was weaker than with hERbwt.
To more quantitatively examine TIF2 interaction to
hERbV320G and hERbwt, we used the SPR analysis, where
biotinylated 14mer peptides containing NR box motifs
(LXXLL) from TIF2 were captured via streptavidin to the
chip surface. Figure 5 illustrates the binding of hERbV320G
and hERbwt in the presence or absence of estradiol to the NR
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Fig. 3. Saturation and Scatchard analyses for [3H]17b-estradiol binding to
hERbwt and hERbV320G. hERbwt and hERbV320G LBDs (20 nM) were
incubated with increasing concentrations (0--20 nM) of [3H]17b-estradiol
at 4C overnight. The inset shows linear transformation of the data
by Scatchard analysis.
Fig. 2. Modeled structure of human ER-b LBD complexed with 17b-
estradiol and the TIF2 co-activator peptide [PBD accession number 1QKM
(29) and human ER-a complexed with 17b-estradiol and the TIF2 co-
activator peptide (1GWR) (50)]. The protein is depicted by a green ribbon/
tube while the ligand estradiol is represented by white and red spheres
(carbon and oxygen atoms, respectively). Helix-12 and the TIF2 co-activator
peptide are depicted in cyan and red, respectively. The positions of the
Lys-314 and Val-320 sidechains are shown as magenta tubes. This figure
was produced using the PyMOL program (http://www.pymol.org).
In
pu
t 
E2 − + − + − +
1 2 3 4 5 6
Fig. 4. Analysis of TIF2 intercation with hERbwt and hERbV320G by
pull-down assay. In vitro translated TIF2 was incubated with hERbwt (lanes
4 and 5) and hERbV320G (lanes 6 and 7), with or without estradiol (E2) as
indicated. Non-specific binding of TIF2 to Talon beads is shown in lanes 2
and 3. Input corresponds to 0.5 ml of the in vitro translation mixture. The
experiment was repeated three times with similar results.
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box of TIF2. The result showed that binding of estradiol to
ERb enhances the affinity of ERb-peptide interaction. Binding
studies were made for the different TIF2 NR box peptides
using five to six different concentrations of hERbwt-LBD or
hERbV320G-LBD unliganded or liganded with estradiol ran-
ging from 0.25 to 2 mM. Affinity determination analysis was
then performed using BIAevaluation software. The curve fit-
ting analysis showed that the model best describing the experi-
mental data was a 1:1 binding with drifting baseline model.
The Kd for binding to TIF2 box1 was 0.23 0.04 mM (mean
SD) and 0.52  0.05 mM and Kd for binding to TIF2 box2 was
0.39  0.1 mM and 0.79  0.1 mM for hERbwt-LBD and
hERbV320G-LBD liganded with estradiol, respectively. The
determined affinities show that hERbV320G displays reduced
affinity for TIF2 as compared with that of wild-type ERb.
Reduced affinity for TIF2 was also seen with unliganded
hERbV320G-LBD as compared with unliganded hERbwt-
LBD (data not shown).
Discussion
In this paper we identify five novel polymorphisms in the
hERb gene in an African population. Interestingly, two of
these polymorphisms are expected to change the correspond-
ing amino acid of the encoded ERb protein. These polymorph-
isms have not been identified in any of the published reports
that describe the characterization of polymorphisms in the
ERb gene in both Caucasians (n ¼ 502) (27) and Asians (n ¼
184) (28). In Africans, the variant protein hERbV320G,
encoded by one of these polymorphic ERb genes, displays
lower maximal transcriptional activity compared with wild-
type ERb. To our knowledge, this represents the first example
of a functional polymorphism in the ERb gene.
The hERbV320G change results in the amino acid sub-
stitution of valine for glycine in helix 4 of the LBD. Helix 4
does not participate directly in binding of the ligand (29).
However, it forms part of the surface that interacts with co-
activators (30). The hERbV320G side chain is in close
proximity to K314, which forms half of the charge-clamp of
the co-activator-binding pocket. Therefore, the hERbV320G
may perturb the conformation of K314, which in turn perturbs
cofactor interactions. Consistent with this, we did not find any
changes in ligand-binding affinity of hERbV320G. However,
this variant displays decreased interaction with the co-activator
TIF2. We propose that reduced co-factor interaction is the cause
for the observed reduced maximal transactivation.
Several endocrine-related diseases show population-based
differences in terms of disease incidence and/or disease pro-
gression but the reason for this racial difference is unclear.
When compared with white American women, African
American women have a higher incidence of breast cancer
before the age of 40 years, and the prognosis after a diagnosed
breast cancer is reported to be poorer at all ages (31). Studies
have suggested that higher plasma levels of insulin-like growth
factor-1 (IGF-1) may account for African American women
having higher risk of premenopausal breast cancer than white
women and may also be an important determinant of breast
cancer risk in postmenopausal women (32--34). A prolonged
exposure to estrogens has been repeatedly found to be asso-
ciated with an increased risk for breast cancer. Racial dispar-
ities in conditions such as postmenopausal obesity, early
menarche and late menopause that all increase endogenous
levels of estrogens may put an African American woman at a
greater risk for breast cancer (35). African American men
present a higher stage of prostate cancer and a worse outcome
of this disease than non-African American men (36). The
increased frequency of prostate cancer among African Amer-
ican men has been attributed to either greater plasma levels of
testosterone (37) or an increased dihydrotestosterone/testoster-
one ratio (38) in this population. Previous studies also revealed
that the plasma level of IGF-1 might be a predictor of prostate
cancer risk (39,40). Some of these racial differences could be
attributed to population differences in genetic polymorphisms.
Polymorphisms involving genes coding for the androgen
receptor, phase I/II enzymes and vitamin D receptor have
been associated with an increased risk of prostate cancer
(41). Polymorphisms that are associated with breast cancer
risk have been identified in the genes involved in a wide
variety of functions including steroid hormone metabolism,
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Fig. 5. SPR analyses of hERbwt and hERbV320G binding to TIF2. The real-time binding sensogram shows injection of 1 mM hERbwt and 1 mM
hERbV320G in the presence or absence of estradiol over a surface immobilized with 200 RU of TIF2 NR box1.
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detoxification of environmental carcinogens and tumor sup-
pressor genes (42).
In this study, we have identified one novel polymorphism in
the ERb gene in an African population that showed decreased
transcriptional activity. Dysregulation of ERb expression has
been reported to be associated with progressions of breast and
prostate cancer (43--46), indicating that ERb functions as a
tumor suppressor gene. The hyperplastic prostate (47) and
dedifferentiated mammary gland (48) phenotypes displayed
by ERb knockout mice support a role for ERb in control of
mammary and prostate growth. Further association studies are
required to determine whether this polymorphism is involved
in the increased incidence of prostate and breast cancers
in Africans.
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ABSTRACT: Estrogens exert their physiological effects through two estrogen receptor (ER) subtypes, ERR
and ERâ. In mouse, the cloning of an alternative splice variant of the wild-type ERâ (mERâ1), mERâ2,
which contains an 18 amino acid insertion in the ligand binding domain, contributed an additional level
of complexity to estrogen signaling. In this study we have assayed the interaction of several known ligands
with mERâ1 and mERâ2. The binding affinity of estradiol was 14-fold higher for mERâ1 than for mERâ2.
In contrast, raloxifene was dramatically (8-fold) mERâ2 selective. The selectivity for mERâ2 was abolished
when the 2-arylbenzothiophene core of the raloxifene molecule was tested for binding affinity,
demonstrating that the 3-aroyl side chain of raloxifene plays an important role in contributing to its mERâ2
selectivity. The opposite isoform selectivity found for estradiol and raloxifene in our ligand binding assay
was also reflected in the transactivation assay system. That is, mERâ2 required 10-fold greater estradiol
concentrations for maximal activation compared to mERâ1, whereas raloxifene was more potent in
antagonizing estradiol-induced gene expression via mERâ2 than mERâ1. The raloxifene core behaved as
a pure agonist. Furthermore, mERâ2 showed significantly decreased estradiol-induced maximal
transcriptional activity as compared to mERâ1. A pull-down assay indicated that the interactions of TIF2
and RAP250 with mERâ2 were weaker than with mERâ1. To assess TIF2 and RAP250 interactions with
ERs more quantitatively, we examined the interaction of LXXLL containing peptides derived from TIF2
and RAP250 with mERâ1 and mERâ2 using surface plasmon resonance analysis. Our results indicate
that mERâ2 interacts with both coactivators with lower affinity, which may explain its reduced
transcriptional activity. Taken together, these results suggest that ligand selectivity and coactivator
recruitment of the ERâ isoforms constitute additional levels of specificity that influence the transcriptional
response in estrogen target cells.
Estrogens exert their physiological effects through two
estrogen receptor (ER)1 subtypes, ERR and ERâ, that belong
to a large family of transcription factors, the nuclear receptor
family (1). ERR and ERâ contain characteristic sequence
motifs associated with transactivation, DNA binding, and
hormone binding (2). They share high homology within the
DNA binding domain and modest homology within the
ligand binding domain (LBD). The LBD is multifunctional
and, in addition to harboring the ligand binding pocket,
encompasses regions for receptor dimerization and ligand-
dependent (AF-2) transactivation (3). Hormone binding to
the ER LBD induces a conformational change in the receptor
that initiates a series of events that culminate in the activation
or repression of responsive genes (4). Although the precise
mechanism by which ER affects gene transcription remains
to be determined, it appears to be mediated, at least in the
case of AF-2 activation, via nuclear receptor coregulators
that are recruited by the DNA-bound receptor (5).
To date, a number of ERâ mRNA isoforms, generated by
alternative mRNA splicing, have been described in human,
mouse, and rat. In mouse, the originally described wild-type
form has been named mERâ1 (6). mERâ2 is an alternative
splice variant where an additional exon is spliced in-frame
between exons 5 and 6 to generate a protein with an 18 amino
acid insertion in the LBD (7). The inserted amino acid
sequence shares significant (16 out of 18 amino acids)
homology with the respective insert in the rat ERâ2 (rERâ2)
isoform (8). It was found that mERâ1 and mERâ2 are
expressed at similar relative levels in some tissues such as
the ovary and lung. However, in a range of tissues such as
liver, pancreas, gut, and bone, mERâ2 mRNA is more
abundant (7, 8). In ligand binding assays ERâ2 binds
estradiol with a lower affinity than ERâ1 (9-12). In a
reporter assay, ERâ2 shows lower transcriptional activity
than ERâ1 and acts as a negative regulator when it is
coexpressed with ERR or ERâ1 (12). The physiological role
of rodent ERâ2 remains to be determined. It was shown that
rERâ2 protein was upregulated during the lactation period,
suggesting that rERâ2 may play a role in silencing of ERR
function during lactation in rat mammary gland (13).
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Ligand-dependent interaction of nuclear receptors and
coactivators is a critical step in nuclear receptor-mediated
transcriptional regulation. The most studied coactivators for
nuclear receptors belong to the steroid receptor coactivator
1 (SRC-1) family, which contains three related members,
referred to as SRC-1, SRC-2/GRIP1/TIF2, and SRC-3/p/CIP/
RAC3/ACTR/AIB1/TRAM1 (14). Critical for the function
of these coactivators is the central nuclear receptor interaction
domain consisting of three equally spaced conserved LXXLL
motifs, also called nuclear receptor boxes. Nuclear receptor-
activating protein 250 (RAP250), also called ASC-2, PRIP,
TRBP, and NRC, was recently cloned and described as a
novel nuclear receptor coactivator consisting of two LXXLL
motifs, of which only the N-terminal motif interacts with
nuclear receptors in general (15).
In this paper we address the characteristics of two mouse
ERâ isoforms, mERâ1 and mERâ2, with regard to ligand
selectivity and transcriptional activation.
EXPERIMENTAL PROCEDURES
Materials. 17â-Estradiol, 4-OH-tamoxifen, genistein, and
raloxifene were from Sigma-Aldrich Sweden AB. ICI-182,-
780 was obtained from Tocris, Inc. The raloxifene core [2-(4-
hydroxyphenyl)benzo[b]thiophen-6-ol] was prepared at Karo
Bio AB (Sweden) according to the method of Jones et al.
(16). The radioligand [3H]-17â-estradiol was purchased from
PerkinElmer Life Sciences Inc.
Plasmids, Transient Transfection Assays, and Western Blot
Analysis. The pSG5-mERâ1 expression plasmid was a gift
from Dr. K. Pettersson at the Department of Biosciences,
Karolinska Institutet. This expression vector includes the
cDNA that encodes the full-length murine ERâ (549 aa) (17).
The murine ERâ2 expression plasmid (pSG5-mERâ2) was
constructed by replacement of the murine ERâ1 cDNA
sequences spanning nucleotides 841-1200 (GenBank,
U81451) with the corresponding region of the murine ERâ2
generated by RT-PCR, using SacI/BstBI restriction sites. The
sequences of the plasmids were verified by DNA sequencing.
HEK293 cells were cultured in a 1:1 mixture of Ham’s
nutrient mixture F12 (Invitrogen) and DMEM (Invitrogen)
supplemented with 5% FBS, 100 units of penicillin/mL, and
100 íg of streptomycin/mL. For transfection, cells were
seeded at a density of 5  104 cells/well in 24-well plates
and cotransfected with 2  ERE TK luciferase reporter
plasmid (0.8 íg) together with pSG5-mERâ1 or pSG5-
mERâ2 (0.016 íg) expression plasmids. A pRL-TK control
plasmid, which contains a Renilla luciferase gene, was
included to control for differences in transfection efficiencies.
Transfections using the Superfect reagent (Qiagen) were
performed according to the manufacturer’s protocol. The
medium was replaced with a phenol red-free mixture of F12
and DMEM containing 5% dextran-coated charcoal-treated
FBS, 100 units of penicillin/mL, and 100 íg of streptomycin/
mL upon transfection. Estradiol, raloxifene, the raloxifene
core, or vehicle (in 0.1% ethanol) was added immediately
after transfection. The cells were harvested 24 h after
transfection, and luciferase activities were determined using
the dual luciferase reporter assay system (Promega) according
to the manufacturer’s instructions.
Western blotting was done according to the protocol as
described (13). ERâ was detected with an ERâ LBD rabbit
polyclonal antibody produced by us as described previously
(18).
Cloning and Expression of mERâ1 and mERâ2 Ligand
Binding Domains. The LBDs of murine ERâ1 (R209 to
Q485, GenBank, U81451) and the corresponding region of
murine ERâ2, containing the 18 aa insertion, were generated
by PCR using pSG5-mERâ1 and pSG5-mERâ2 as templates,
respectively, and primers that contained appropriate restric-
tion sites. The LBDs of mERâ1 and mERâ2 were cloned
into pET15b (Novagen, Madison, WI) to generate proteins
with N-terminal His tags. The sequences of the constructs
were verified by DNA sequencing.
Cultures (500 mL) of the Escherichia coli strain BL21,
transformed with the appropriate expression plasmids, were
cultivated overnight in LB supplemented with 100 íg/mL
ampicillin at 37 °C. When the OD600 reached 1.0, IPTG was
added to a final concentration of 1 mM and incubation
continued for 3 h at 25 °C. The cells were pelleted, and the
supernatant was discarded. The pellet was suspended in 5
mL of extraction buffer (0.3 M NaCl, 20 mM Tris-HCl, pH
8.0, 0.01 mg/mL DNase, 0.01 mg/mL RNase, 10 mM MgCl2,
0.25 mg/mL lysozyme, 1 mM â-mercaptoethanol, and
protease inhibitor cocktail tablet). The samples were soni-
cated for 4 min at 50% duty (total sonication time 2 min).
The homogenate was centrifuged at 20000g for 20 min at 4
°C. The supernatant was applied to a TALON metal affinity
column (Clontech Laboratories, Inc., Palo Alto, CA). Frac-
tions containing the purified protein were dialyzed against
20 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 1 mM DTT
and frozen at -80 °C. The purified protein was more than
95% pure as determined from Coomassie-stained SDS-
PAGE gels. The protein concentrations were measured using
the Coomassie protein assay kit (Pierce, Rockford, IL)
according to the manufacturer’s instructions.
Scintillation Proximity Assay (SPA). The assay was
performed in 96-well microplates (PerkinElmer Life Sciences
Inc., Boston, MA). Polyvinyltoluene (PVT) copper-loaded
His-tag beads were purchased from Amersham Corp. The
reaction mixture (60 íL per well) containing assay buffer
(1 mM EDTA, 0.9 M KH2PO4, 0.1 M K2HPO4, 20 mM Na2-
MoO4, and 0.05% monothioglycerol), beads (30 íg/well),
and purified ERâ LBD (final concentration of 5 nM) was
incubated at 4 °C for at least 1 h. The concentration of active
receptors that are able to bind ligand was 0.6 nM, calculated
from Bmax (the maximal density of receptor sites). For
saturation ligand binding analysis, a sample of various
concentrations of [3H]-17â-estradiol (SA ) 95 Ci/mmol) in
the presence or absence of a 300-fold excess of unlabeled
17â-estradiol was then added. The assay plates were sealed,
allowed to settle overnight, and subsequently counted on a
Wallac 1450 micro-â-counter. The dissociation constant (Kd)
was calculated as the free concentration of radioligand at
half-maximal specific binding by fitting data to the Hill
equation and by linear Scatchard transformation (19). Curve
fitting was done in Prism (GraphPad Software Inc.).
For ligand competition studies, purified ERâ LBDs (5 nM)
were incubated overnight at 4 °C with a range of test
compound concentrations. A final concentration of 1.5 nM
[3H]-17â-estradiol (30 íL per well) was used. The ligands
were tested three times with similar results. Curve fitting
was performed using Prism (GraphPad Software Inc.), and
the IC50s were determined. IC50 values were converted to Ki
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using the Cheng-Prusoff equation, Ki ) IC50/(1 + D/Kd),
where D is the concentration of the radioligand (20).
Surface Plasmon Resonance (SPR) Analysis for Raloxifene
Binding. SPR analyses were performed according to the
protocol as described (21). Research grade CM5 sensor chips
were obtained from BIAcore AB. Penta-His antibody (Qiagen)
surfaces were prepared using standard amine coupling
procedures.
Plasmids and Pull-Down Assay. TIF2 and RAP250 for in
vitro translation were expressed from the previously de-
scribed plasmids, pSG5Gal4-RAP250 (aa 819-1096) (15)
containing the first LXXLL motif and pBKCMV-TIF2 (22)
containing full-length TIF2, respectively.
For pull-down assays, purified His-tagged ERâ LBDs (100
íg) were bound to 60 íL of Talon resin and then equilibrated
in 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM MgCl2,
10% glycerol, and 0.5% NP-40 (equilibration buffer). The
gel slurry was then divided into two equal aliquots, and to
each tube was added 2.5 íL of in vitro translated, 35S-labeled
(TNT coupled reticulocyte lysate system, Promega), TIF2
or RAP250 in a total volume of 150 íL of equilibration
buffer containing 1.5% BSA. Estradiol or vehicle (ethanol)
was added as indicated. As control, TIF2 or RAP250 was
mixed with Talon gel without bound ERâ. All samples were
incubated for 2 h with gentle shaking at 4 °C. After washing
three times with equilibration buffer, bound proteins were
eluted with SDS-PAGE sample buffer and separated on a
12% polyacrylamide gel. The gel was stained with Coo-
massie blue, followed by determination of 35S using a
Phosphoimager instrument.
Surface Plasmon Resonance (SPR) Analysis for Coacti-
Vator Binding. All SPR measurements were performed on a
BIAcore 2000 instrument (BIAcore AB, Uppsala, Sweden).
All experiments were performed at 25 °C and at a flow rate
of 5 íL/min. Research grade streptavidin sensor chips were
obtained from BIAcore AB. The streptavidin chips were first
treated with three 1-min pulses of 50 mM NaOH and 1 M
NaCl at a flow rate of 5 íL/min. N-Terminally biotinylated
peptides (>95% purity) were purchased from Interactiva
(Germany). LXXLL peptide sequences were as follows:
TIF2 Box1 (residues 636-649), KGQTKLLQLLTTKS;
TIF2 Box2 (residues 685-698), EKHKILHRLLQDSS; TIF2
Box3 (residues 742-755), KENALLRYLLDKDD; RAP250
Box1 (residues 882-895), LTSPLLVNLLQSDI. Peptides
were immobilized on individual surfaces to 200 RU re-
sponses, and a non-LXXLL peptide was immobilized on a
control surface for on-line reference subtraction. Samples
of purified mERâ1 LBD or mERâ2 LBD were then injected
over each surface. After injection stopped, the surfaces were
washed with buffer to monitor the dissociation phase. The
buffer used was 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1
mM EDTA, and 0.05% Tween 20. For the kinetic measure-
ments, various concentrations of mERâ1 LBD or mERâ2
LBD (from 20 to 100 nM) were injected over the chip
surfaces. The BIAevaluation software version 3.1 was used
for evaluation. Different binding models (different rate
equations) were tested in the global curve fitting procedure,
and the model best describing the experimental data was a
conformational change model. The apparent KD values are
calculated as described (23).
RESULTS
mERâ1 and mERâ2 Display Isoform SelectiVity with
Regard to Ligand Binding. The C-terminal regions containing
the LBD of mERâ1 and mERâ2 were expressed in E. coli,
and the recombinant proteins were purified. Ligand binding
to purified proteins was measured using a scintillation
proximity assay. In Figure 1, the results of saturation ligand
binding assays with tritiated estradiol are shown. The
measured Kd values were 0.8 nM for mERâ1 and 5-fold
higher (Kd ) 4.2 nM) for mERâ2. We next compared the
binding affinities of mERâ1 and mERâ2 to a set of ER
ligands using a competition assay. Table 1 shows the Kis of
these compounds. As expected, the selectivity of estradiol
was higher for mERâ1 than for mERâ2 (14-fold). Interest-
ingly, raloxifene was dramatically (8-fold) mERâ2 selective.
When the raloxifene core was tested in the ligand binding
assays, the selectivity for mERâ2 was abolished, confirming
that the selectivity for mERâ2 was due to, at least in part,
the 3-aroyl side chain of raloxifene. No striking differences
in the binding affinities for 4-OH-tamoxifen, ICI-182,780,
or genistein between mERâ1 and mERâ2 could be detected.
These data indicate that ER ligands exhibit distinct selectivity
for mouse ERâ isoforms.
To further confirm the higher binding affinity of mERâ2
compared to mERâ1 for raloxifene, we used SPR analysis
to directly assay binding affinities. Figure 2 depicts the
binding responses obtained for the concentration series of
raloxifene injected across the mERâ1 or mERâ2 surface. It
is clear from a visual inspection of the data that raloxifene
dissociates from the mERâ1 faster than the mERâ2 isoform.
The measured KD values were 0.31 íM for mERâ1 and 10-
fold lower (KD ) 0.03 íM) for mERâ2, confirming that
raloxifene has a higher affinity for mERâ2 as compared to
mERâ1.
mERâ1 and mERâ2 Isoform SelectiVity Is Maintained in
Transcriptional Regulation. Estradiol and raloxifene exhib-
ited different isoform selectivity with regard to ligand binding
for the mouse ERâ. Next, we examined how this selectivity
was translated into modulation of transcriptional activity.
Estradiol induced a concentration-dependent activation of
mERâ1 and mERâ2 from a 2  ERE driven reporter gene
in transiently transfected HEK293 cells (Figure 3A). Notably,
mERâ1 had higher estradiol-induced activity than mERâ2.
FIGURE 1: Saturation analyses for [3H]-17â-estradiol binding to
mERâ1 and mERâ2. mERâ1 (b) and mERâ2 (O) LBDs were
incubated with increasing concentrations (0-30 nM) of [3H]-17â-
estradiol at 4 °C overnight. Nonlinear regression in Prism (GraphPad
Software) of the data gives a Kd of 0.8 nM for mERâ1 and a Kd of
4.2 nM for mERâ2.
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Thus, maximal transcriptional activation by mERâ1 was
observed at 1 nM estradiol, whereas maximal transactivation
by mERâ2 was observed at 10 nM estradiol, at only 60% of
the maximal level seen with mERâ1. Raloxifene showed only
antagonist activity on both mERâ1 and mERâ2. As shown
in Figure 3B, raloxifene was more potent in antagonizing
estradiol-induced gene expression with mERâ2 than with
mERâ1, which is in agreement with its higher relative
binding affinity to mERâ2 than to mERâ1. In contrast to
raloxifene, the raloxifene core behaved as a pure agonist for
both mERâ1 and mERâ2 (Figure 3C). To confirm equivalent
ERâ expression, extracts from HEK293 cells transfected with
equal amounts of the expression vectors for mERâ1 or
mERâ2 used in transient transfection assays were separated
by SDS-PAGE and analyzed for ERâ expression by
Western blot (Figure 3D). This analysis shows that mERâ1
and mERâ2 are expressed at similar levels.
mERâ2 Has Reduced Interaction with CoactiVators. As
shown in Figure 3A, mERâ2 displayed significantly de-
creased estradiol-induced maximal transcriptional activity as
compared to mERâ1. Because the interaction of ER with
coactivators is believed to determine the magnitude of
transcriptional activity of the receptor, we compared the
affinities of mERâ1 and mERâ2 to the coactivators TIF2
and RAP250. We performed pull-down assays using purified
His-tagged ERâ LBDs and 35S-labeled TIF2 or RAP250 in
the presence or absence of estradiol. As shown in Figure 4,
the binding of TIF2 and RAP250 to mERâ1 and mERâ2
appeared to be enhanced by the presence of estradiol.
Furthermore, the interactions of TIF2 and RAP250 with
mERâ2 were weaker than with mERâ1.
To examine interactions of TIF2 and RAP250 with ERs
more quantitatively, we used SPR analysis, where biotiny-
lated 14-mer peptides containing NR-box motifs (LXXLL)
from TIF2 or RAP250 were captured via streptavidin to the
chip surface. Figure 5A demonstrates overlaid sensorgrams
of injections of unliganded mERâ2 or mERâ2 liganded with
estradiol, 4-OH-tamoxifen, genistein, ICI-182,780, or raloxi-
fene assayed for binding to the TIF2 NR-Box2 peptide. These
results indicate that binding of ER agonists, estradiol and
genistein, to mERâ2 enhances the mERâ2-peptide interac-
tion, whereas 4-OH-tamoxifen, ICI-182,780, and raloxifene
decrease the affinity. Similar differences in binding, depend-
ing on ligand status, were seen with mERâ1 and also with
RAP250 interaction (data not shown). These data suggest
that conformational changes, induced by ligand binding,
impose different affinities for receptor-coactivator interac-
tions. In Figure 5B, the concentration-dependent association
of estradiol-bound mERâ2 to RAP250 NR-Box1 or TIF2
NR-Box2 is shown together with the best calculated fit.
Similar binding studies between mERâ1 and all the different
TIF2 and RAP250 NR-box peptides were also performed
(data not shown). Using BIAevaluation software, the affinity
of receptor-peptide interaction was determined. The best
Table 1: Binding Affinity of Selected Ligands for mERâ1 and
mERâ2
FIGURE 2: Kinetic analysis of raloxifene binding to mERâ1 and
mERâ2. Raloxifene was injected at concentrations of 0.03125,
0.0625, 0.125, 0.25, and 0.5 íM over captured mERâ1 (A) and
mERâ2 (B). The data were best described using a simple 1:1
interaction model, yielding a KD of 0.31 íM for mERâ1 and a KD
of 0.03 íM for mERâ2.
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fit for all peptide-ER interactions tested was obtained using
a conformational change model. The apparent affinities listed
in Table 2 show that the TIF2 peptides have higher affinity
for mERâ1 and mERâ2 than the RAP250 peptide. The data
also show that both TIF2 and RAP250 have binding
preferences for mERâ1. In comparison to mERâ1, the lower
affinity of mERâ2 to coactivators may account for its reduced
maximal transcriptional activity.
DISCUSSION
Since 1997, when a new isoform of the rat ERâ gene
named ERâ2 was identified (8), only a few studies have
addressed the function of this variant (9-12). It has been
shown that ERâ2 binds estradiol with a lower affinity than
ERâ1. ERâ2 can form heterodimers with ERâ1 as well as
with ERR. Further, transient coexpression of ERâ2 and ERR
or ERâ1 in cell lines results in ERâ2-induced reduction of
ERR and ERâ1 activity. In this paper, we have addressed
the effect of ligand binding selectivity and ligand-induced
recruitment of coactivators on the transcriptional activation
profiles of mouse ERâ1 and ERâ2.
It is predicted that the 18 amino acid insertion of ERâ2
lies within helix 6 of the receptor (24). Given that the
insertion is right after the â-sheet that contains Phe-356,
which makes direct contact with the ligands, and in close
proximity to helix 5, known to have direct interactions with
coactivators, the inserted amino acids might affect both
ligand binding and coactivator interactions. We have com-
pared the binding affinities of mERâ1 and mERâ2 to a set
of ER ligands. In accordance with previous studies, our
results show that the binding affinity of estradiol for mERâ1
was much higher than for mERâ2. On the contrary, ralox-
ifene was found to be dramatically mERâ2 selective. The
differences found for estradiol and raloxifene in our ligand
binding assay were also reflected in the transactivation assay.
This observation suggests that raloxifene could act as a potent
antagonist of ERâ2 actions and that this differential ralox-
ifene sensitivity may represent a way to dissect the physi-
ological importance of ERâ2. Furthermore, we demonstrated
that the raloxifene core behaved as an agonist, showing that
the selective antagonist potency of raloxifene for mERâ2 is
due to its 3-aroyl side chain. Raloxifene but not 4-OH-
tamoxifen or ICI has been shown to be a higher affinity
ligand and a more potent estrogen antagonist for human ERR
than ERâ (25). Therefore, the mERâ2 binding selectivity
for these three ligands more closely resembles that of ERR
than of mERâ1. In the present study, we also observed that
mERâ2 showed significantly decreased estradiol-induced
maximal transcriptional activity than mERâ1. We therefore
evaluated the affinities of mERâ1 and mERâ2 for coacti-
vators TIF2 and RAP250. Our results indicate that mERâ2
interacts with both coactivators with lower affinity than
mERâ1, which may explain why the transcriptional activity
of mERâ2 is lower than that of mERâ1.
A detailed understanding of why raloxifene is selective
for mERâ2 over mERâ1 is not possible since no crystal-
lographic structure of the ERâ2 isoform is currently avail-
able. However, a comparison of the existing raloxifene
structures complexed with hERR (26) (PDB accession code
1ERR) and rERâ1 (27) (PDB accession code 1QKN) is
instructive. As mentioned above, the raloxifene binding
characteristics of mERâ2 more closely resemble ERR than
ERâ1. As shown in Figure 6A, Phe-322 in the ERâ/
raloxifene crystallographic structure is pointed toward the
ligand forcing the 2-aryl group of raloxifene upward. As a
consequence, the hydrogen bond between His-430 and the
4′-hydroxyl group of raloxifene is weakened (OâââH-N angle
FIGURE 3: Transcriptional activity of mERâ1 and mERâ2 proteins
assayed on 2  ERE TK luciferase reporter. HEK293 cells were
transfected with the 2  ERE TK luciferase reporter plasmid and
expression plasmids encoding mERâ1 or mERâ2. (A) Cells were
treated with vehicle (ethanol) or the indicated concentrations of
17â-estradiol. (B) Antagonist potency of raloxifene for mERâ1 and
mERâ2 in the presence of 10 nM 17â-estradiol. Cells were treated
with vehicle (ethanol) or the indicated concentrations of raloxifene.
Values obtained from cells treated with only 10 nM 17â-estradiol
were arbitrarily set to 100. (C) Cells were treated with vehicle
(ethanol) or the indicated concentrations of the raloxifene core.
Values represent the mean ( SD of three independent experiments.
(D) Western blot analysis of ERâ and â-actin. Identical amounts
(100 íg of protein) of whole cell extracts from nontransfected
control HEK293 cells or cells transfected with equal amounts of
expression vectors for mERâ1 and mERâ2, respectively, were
analyzed. The bands were quantified by densitometric scanning,
and the amount of ERâ was normalized to â-actin.
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) 145° vs 180° for an ideal hydrogen bond). In contrast,
the corresponding Phe-425 is pointed away from the ligand
in the ERR crystallographic structure, allowing more flex-
ibility for positioning of the ligand in the binding cavity,
and consequently the hydrogen bond between His-524 and
the 4′-hydroxyl group is stronger (OâââH-N angle ) 165°
in 1ERR). Hence the conformation of Phe-322 is an
important determinant of the affinity of the various ER
isoforms for raloxifene. Now turning to ERâ2, the insert
between Arg-364 and Asp-365 on helix 6 is very close to
Phe-322 (Figure 6A) and therefore could easily influence
the preferred conformation of this phenylalanine residue. The
ERâ2 insert may perturb the conformation of Phe-322 so
that it behaves more like in ERR, making more room for
the 2-aryl group of raloxifene so that in turn the 4′-hydroxyl
group can form a stronger hydrogen bond to His-430. This
would account for the increased affinity of raloxifene for
ERâ2. The explanation for why raloxifene but not the
raloxifene core is ERâ2 selective can be understood by
comparing the crystallographic structure of ERR complexed
FIGURE 4: Analysis of TIF2 (A) and RAP250 (B) interactions with mERâ1 and mERâ2 by pull-down assay. In vitro translated TIF2 or
RAP250 was incubated with mERâ1 (lanes 3 and 4) and mERâ2 (lanes 5 and 6), with or without estradiol (E2) as indicated. Nonspecific
binding of TIF2 or RAP250 to Talon beads is shown in lanes 1 and 2. Input corresponds to 0.5 íL of the in vitro translation mixture. The
amount of loaded mERâ1 (lanes 3 and 4) and mERâ2 (lanes 5 and 6) was examined by Coomassie blue staining (middle panel). The bar
graph shows the relative binding of mERâ1 (lanes 3 and 4) and mERâ2 (lanes 5 and 6) to TIF2 or RAP250 compared to the amount of
loaded protein, as determined by densitometric scanning. The relative binding of mERâ1 to TIF2 or RAP250 in the absence of estradiol
was set to 1. Nonspecific binding of TIF2 or RAP250 to a 6  His control protein, which does not interact with coactivators, could not be
detected using the experimental conditions employed (data not shown).
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with the raloxifene core (PDB accession code 1GWQ) (28)
to the two raloxifene structures, 1ERR and 1QKN (see Figure
6B). The raloxifene core binds to ER in a flipped orientation
relative to raloxifene. In this binding mode, the 6-hydroxyl
group of the raloxifene core forms a strong hydrogen bond
to His-524 (OâââH-N angle ) 179°). Also, in this flipped
orientation, the distance between the raloxifene core and
Phe-425 is larger so that it is less sensitive to the conforma-
tion of this phenylalanine residue. In contrast, the 3-aroyl
side chain forces the benzothiophene moiety of raloxifene
to bind in a flipped orientation relative to the raloxifene core
and pushes the 2-aryl group toward Phe-322.
The biological significance of the existence of two main
ERâ isoforms in rat and mouse is presently unclear. Given
that ERâ2 suppressed the ERR-mediated transcriptional
response, one possibility is that ERâ2 acts as a negative
regulatory partner of ERR under specific physiological
conditions. It has been demonstrated that ERâ1 acts as
modulator of ERR-mediated gene transcription in mouse
uterus (29). Furthermore, it was found that the ERâ2 protein
is upregulated and the colocalization of ERâ2 with ERR is
increased during the lactation period in rat mammary gland,
indicating a possible role of ERâ2 as a dominant repressor
of ERR (13). Our study and those of others demonstrate that
the two receptor isoforms show differences in response to
estradiol and other ligands. It is thus also possible that
regulation of receptor isoform expression could govern the
tissue effects of specific estrogenic agents. The other
possibility is that ERâ2 provides a cellular mechanism to
respond to elevated estradiol levels, e.g., achieved in the
ovary during pregnancy or the periovulatory phase, higher
than those required to fully activate ERR and ERâ1. In
addition, it cannot be excluded that there exist phyto- or
xenoestrogens that act preferentially at ERâ2. ERâ2 may
also have other functions. For example, it was shown that,
in the presence of estradiol or raloxifene, ERâ2 can activate
the transforming growth factor â promoter as efficiently as
ERR and ERâ1 (11).
In mouse and rat, the tissue distribution and/or the relative
levels of ERâ1 and ERâ2 mRNA seem to be quite different,
that is, high expression in liver, pancreas, uterus, breast, and
brain for ERâ2 and in nervous system for ERâ1 (30),
FIGURE 5: SPR analysis of LXXLL peptide binding to mERâ2.
(A) Overlaid sensorgrams showing injections of 100 nM unliganded
mERâ2 and mERâ2 liganded with estradiol, genistein, ICI-182,-
780, raloxifene, or 4-OH-tamoxifen, respectively, over a surface
captured with 200 RU of TIF2 NR-Box2 peptide. Ligand concen-
trations of 1 íM were used. (B) Overlaid sensorgrams showing
injections of mERâ2 liganded with 1 íM estradiol at protein
concentrations of 20, 40, 60, 80, and 100 nM over a surface captured
with 200 RU of RAP250 NR-Box1 peptide or TIF2 NR-Box2 (solid
lines) and best calculated fit using a conformational change model
(dotted lines).
Table 2: Apparent Dissociation Constants and Rate Constants for
Interactions between TIF2 or RAP250 NR-Box Peptides and
Estradiol-Bound mERâ1 and mERâ2a
TIF2 RAP250
mERâ1 Box1 Box2 Box3 Box1
KD (nM) 7.3 ( 2.9 4.2 ( 0.8 12.7 ( 4.1 41.5 ( 6.9
ka1  104
(M-1 s-1)
12.1 ( 1.0 35.3 ( 2.3 15.1 ( 0.6 10.9 ( 0.3
kd1  10-3
(s-1)
3.4 ( 0.6 3.6 ( 0.8 3.3 ( 0.9 6.1 ( 0.1
ka2  10-3
(s-1)
1.9 ( 0.1 1.2 ( 0.2 1.8 ( 0.2 2.3 ( 0.1
kd2  10-3
(s-1)
0.5 ( 0.1 0.5 ( 0.1 1.0 ( 0.3 1.7 ( 0.2
TIF2 RAP250
mERâ2 Box1 Box2 Box3 Box1
KD (nM) 66.3 ( 23.2 63.7 ( 21.2 120.8 ( 30.5 272.3 ( 82.4
ka1  104
(M-1 s-1)
4.6 ( 1.2 4.5 ( 0.6 3.4 ( 0.3 6.0 ( 0.8
kd1  10-3
(s-1)
6.2 ( 0.8 5.1 ( 0.6 5.6 ( 1.0 32.3 ( 2.6
ka2  10-3
(s-1)
2.0 ( 0.2 1.8 ( 0.1 1.5 ( 0.1 4.5 ( 1.0
kd2  10-3
(s-1)
1.0 ( 0.1 1.0 ( 0.1 1.1 ( 0.2 2.3 ( 0.4
a The apparent KD values were obtained from SPR-generated data
using the curve fitting analysis program BIAevaluation. The data were
best described using a conformational change model according to
equation
A + B y\z
ka1
kd1
AB y\z
ka2
kd2
AB*
The receptor (A) first forms an unstable complex (AB) with the peptide
(B) and then undergoes a conformational change that leads to a more
stable complex (AB*). KD ) (kd1/ka1)(kd2/ka2). Values represent the mean
( SD of three independent experiments.
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implying a specific mechanism regulating expression of one
or the other splice variant. In humans, tissue-specific
expression of the ERR gene has been shown to be regulated
by multiple promoters (31). Further studies, including cloning
and characterization of putative promoters, should help to
elucidate the regulatory mechanisms of ERâ isoform expres-
sion. Interestingly, the expression of ERâ2 mRNA has been
demonstrated in various human cancer cell lines (9). A
variant of ERR, analogous to ERâ2, which contains an in-
frame insertion between exons 5 and 6 that encodes an
additional 23 amino acids in the LBD has been reported in
human breast cancers (32). In breast, raloxifene acts as a
classical antiestrogen to inhibit the growth of mammary
carcinoma (33). Our findings that raloxifene binds prefer-
entially to ERâ2 imply that the varying expression of ERâ
isoforms under certain conditions might have important
pharmacological implications.
Selective estrogen receptor modulators (SERMs) are
developed to display either agonist or antagonist activity in
a tissue-selective manner and are likely to provide novel and
improved therapeutic strategies. Although the mechanisms
by which these ligands accomplish tissue-selective activity
remain to be fully elucidated, multiple ERs provide op-
portunities for the synthesis of receptor-selective ligands as
one class of SERMs. However, isoform-dependent ligand
selectivity, reported for the two rodent ERâs in this study,
needs to be considered when novel compounds are tested in
animal studies.
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Recent studies have established that ampliﬁcation of the
MET proto-oncogene can cause resistance to epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) in non-small cell lung cancer (NSCLC) cell lines
with EGFR-activating mutations. The role of non-
ampliﬁed MET in EGFR-dependent signaling before
TKI resistance, however, is not well understood. Using
NSCLC cell lines and transgenic models, we demonstrate
here that EGFR activation by either mutation or ligand
binding increases MET gene expression and protein levels.
Our analysis of 202 NSCLC patient specimens was
consistent with these observations: levels of MET were
signiﬁcantly higher in NSCLC with EGFR mutations than
in NSCLC with wild-type EGFR. EGFR regulation of
MET levels in cell lines occurred through the hypoxia-
inducible factor (HIF)-1a pathway in a hypoxia-independent
manner. This regulation was lost, however, after MET
gene ampliﬁcation or overexpression of a constitutively
active form of HIF-1a. EGFR- and hypoxia-induced
invasiveness of NSCLC cells, but not cell survival, were
found to be MET dependent. These ﬁndings establish that,
absent MET ampliﬁcation, EGFR signaling can regulate
MET levels through HIF-1a and that MET is a key
downstream mediator of EGFR-induced invasiveness in
EGFR-dependent NSCLC cells.
Oncogene (2010) 29, 2616–2627; doi:10.1038/onc.2010.16;
published online 15 February 2010
Keywords: EGFR; MET; non-small cell lung cancer;
HIF-1a; invasiveness
Introduction
Non-small cell lung cancer (NSCLC) is the leading cause
of cancer death in the United States. Epidermal growth
factor receptor (EGFR)-activating mutations have been
described in a subset of NSCLC patients, and activated
EGFR is known to inﬂuence tumor cell survival,
proliferation, angiogenesis, and invasiveness (Lynch
et al., 2004; Paez et al., 2004; Pao et al., 2004; Janne
et al., 2005; Pao and Miller, 2005; Ciardiello and
Tortora, 2008). EGFR tyrosine kinase inhibitors (TKIs)
such as erlotinib and geﬁtinib are clinically active in
10–20% of NSCLC patients (Fukuoka et al., 2003; Kris
et al., 2003; Shepherd et al., 2005; Thatcher et al., 2005).
Activating mutations within the EGFR tyrosine kinase
domain including an amino acid substitution at exon 21
(L858R) and in-frame deletions in exon 19 were found
to be predictors of clinical response to EGFR TKIs
(Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004).
Recent evidence suggests that in NSCLC cells
activating EGFR mutations or ampliﬁcation of the
MET proto-oncogene caused acquired resistance to
EGFR TKIs by driving activation of the PI3K pathway
(Engelman et al., 2007). The role of MET in EGFR-
dependent signaling before the emergence of TKI
resistance is not well understood; however, MET is
regulated by hypoxia and hypoxia-inducible factor-1a
(HIF-1a) and is thought to contribute to invasive tumor
growth (Pennacchietti et al., 2003). The MET protein is
a receptor tyrosine kinases whose activation can cause
malignant transformation and tumorigenesis (Cooper
et al., 1986; Park et al., 1987; Stabile et al., 2004). Upon
ligand binding, MET activates downstream signaling
molecules including PI3K, Src, and signal transducer
and activator of transcription-3 (Rosario and Birchmeier,
2003), triggering the key metastatic steps of cell
dissociation (Qiao et al., 2002), migration (Yi et al.,
1998), and invasion (Bredin et al., 2003). MET is
overexpressed in multiple malignancies and is associated
with aggressive disease (Peruzzi and Bottaro, 2006). In
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NSCLC, MET levels are elevated in resected tumors
compared with normal tissue (Liu and Tsao, 1993;
Ichimura et al., 1996; Olivero et al., 1996), and high
expression of the MET ligand hepatocyte growth factor
(HGF) is associated with aggressive disease and a poor
prognosis (Siegfried et al., 1998).
Recent studies have suggested a link between EGFR
signaling and MET. Expression and phosphorylation of
EGFR and MET correlate in multiple malignancies
(Weinberger et al., 2005). Aberrant EGFR activation
results in elevated MET phosphorylation in thyroid
carcinoma cells (Bergstrom et al., 2000). EGFR function
has been implicated in HGF-induced hepatocyte pro-
liferation (Scheving et al., 2002) and is required for
MET-mediated colon cancer cell invasiveness (Pai et al.,
2003). Recent studies of phosphoprotein networks
reveal an association between EGFR and MET activa-
tion (Huang et al., 2007; Guo et al., 2008), and have
reported direct crosstalk between EGFR and the MET
(Jo et al., 2000; Huang et al., 2007).
A plausible link between the EGFR and MET
pathways is HIF-1, which has two subunits (HIF-1a
and HIF-1b), and is known to contribute to tumor cell
motility and invasiveness. EGF has been shown to
modulate HIF-1a levels in prostate, breast, and lung
cancer cell lines (Zhong et al., 2000; Phillips et al., 2005;
Peng et al., 2006), and positive correlations between
EGFR and HIF-1a expression have been observed in
NSCLC (Hirami et al., 2004; Swinson et al., 2004).
Here, we have used clinical specimens, transgenic
mouse models, and cell lines to investigate the hypo-
thesis that EGFR signaling may regulate MET levels
through HIF-1a but that MET ampliﬁcation, which
occurs in EGFR TKI resistance, would uncouple MET
levels from EGFR regulation. We hypothesized further
that EGFR-induced invasiveness, like hypoxia-induced
invasiveness, is mediated downstream at least in part by
the HIF-1a/MET axis.
Results
EGFR-activating mutations are associated with elevated
levels of MET in NSCLC clinical samples
To investigate a possible association between EGFR
activation and MET in clinical specimens, we evaluated
MET levels by immunohistochemistry and assessed
EGFR mutations in 202 human NSCLC clinical speci-
mens. Out of 202 samples, 22 had detectable EGFR
mutations. Specimens were immunostained for MET
and scored based on an intensity score (0, 1, 2, or 3)
and an extension percentage. The ﬁnal score was the
product of these two values. The mean score for MET
expression was 39.46±64.52. Therefore, a score of 40
was considered the cutoff for classifying low and
high levels of MET expression. The mean MET
expression score was signiﬁcantly higher in specimens
with mutated EGFR (73.64±70.68) than in specimens
with WT EGFR (48.72±71.72; P¼ 0.04; Figure 1a).
Furthermore, 37% of NSCLC tumors with WT EGFR
expressed high levels of membranous MET, whereas
68% of NSCLC tumors with mutated EGFR expressed
high levels of membranous MET (P¼ 0.005; Figure 1b).
Among adenocarcinomas with EGFR-activating muta-
tions, we did not observe any association between
EGFR expression and survival. However, considering
the small sample size, no deﬁnitive conclusions can
be drawn.
EGFR activation modulates MET expression
in transgenic murine models of NSCLC
We investigated whether a similar association between
EGFR-activating mutations and MET expression
occurred in murine models of NSCLC. We used
transgenic mice with lung tumors driven by lung-
speciﬁc mutated K-RAS or activating EGFR mutation
(Forsythe et al., 1996; Johnson et al., 2001). Lung
tumor sections were immunostained for MET and
scored as described above. K-RAS-driven lesions had an
average score of 6.75, whereas tumors with EGFR-
activating mutations had an average staining score of
40.65 (Figure 1c; Po0.001). Treatment of mice bearing
EGFR-driven lung tumors with the EGFR TKI
erlotinib (50mg/kg/day) for 48 h abolished MET,
providing evidence that MET levels were regulated by
EGFR activation.
EGFR-activating mutations are associated with elevated
HIF-1a and MET levels in NSCLC cell lines
Given our ﬁnding that tumors with EGFR mutations
exhibit higher MET expression, we investigated MET
regulation by EGFR and its role in EGFR-mediated
NSCLC invasiveness. We evaluatedMET RNA levels in
NSCLC cell lines by performing gene expression
analysis on gene arrays of 53 previously characterized
NSCLC lines (eight lines with mutated EGFR) (GEO
4824) (Zhou et al., 2006). MET RNA levels were
signiﬁcantly higher in EGFR-mutated cell lines than in
NSCLC cell lines expressing WT EGFR (Figure 2a;
P¼ 0.002); however, MET expression levels in cell lines
with K-RAS mutations were not signiﬁcantly different
compared with cell lines with WT K-RAS. Moreover, we
observed a signiﬁcant association between EGFR gene
copy number (44 copies using RT–PCR) and levels of
MET expression (P¼ 0.03, Figure 2b).
We evaluated MET protein levels in NSCLC with or
without EGFR-activating mutations and observed con-
stitutive EGFR phosphorylation in cell lines with
mutated EGFR, which was associated with increased
phosphorylated MET (p-MET) and MET expression
(Figure 2c). Cell lines with EGFR-activating mutations
were positive for HIF-1a expression in normoxia.
HCC827 cells, which exhibited the most robust expres-
sion of p-EGFR, produced the highest levels of HIF-1a,
p-MET, and MET. Western data are supported by
ELISA analysis showing higher levels of p-EGFR,
p-MET, and HIF-1a in cell lines with EGFR-activating
mutations compared with cells with WT EGFR
(Figures 2d–f).
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Activated EGFR modulates p-MET, MET, and HIF-1a
We treated HCC827 cells with 1 mM of erlotinib for
12 h and evaluated p-MET, MET, and HIF-1a levels.
Erlotinib reduced p-MET and MET protein (Figure 3a).
EGFR inhibition resulted in diminished HIF-1a levels.
p-MET, MET, and p-EGFR were further analyzed
by ELISA assay (Figure 3b). Consistant with data
obtained by western blot, erlotinib decreased p-EGFR
(P¼ 0.009), p-MET (P¼ 0.1), and MET (P¼ 0.001)
levels. As HIF-1a is known to regulate MET transcrip-
tion, we determined whether mutated EGFR would
regulate MET mRNA levels. We treated HCC827 cells
with or without erlotinib (1 mM) for 12 h and collected
RNA for RT–PCR to evaluate changes in MET mRNA
relative to GAPDH RNA. Inhibition of EGFR activity
resulted in approximately a 50% decrease inMET RNA
compared with control levels (Figure 3c).
To further show that EGFR signaling modulates
HIF-1a and MET protein expression, we transfected
HCC827 cells with control siRNA and EGFR-, HIF-1a-,
and MET-targeting siRNA. Knockdown of EGFR
decreased p-MET, MET, and HIF-1a levels. HIF-1a-
targeting siRNA did not alter EGFR expression but
reduced MET expression and activation, whereas MET
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siRNA reduced MET but not EGFR or HIF-1a
levels (Figure 3d), indicating that HIF-1a and MET
are downstream of EGFR. Similar results were ob-
tained by HIF-1a ELISA assay. siRNA directed against
EGFR but not MET decreased HIF-1a levels (P¼ 0.009;
Figure 3e).
MET ampliﬁcation has been described in a subset of
NSCLC patients (Zhao et al., 2005; Engelman et al.,
2007). To determine whether MET ampliﬁcation would
result in MET expression that was independent of
EGFR, we treated H1993 NSCLC cells, which harbor
an ampliﬁed MET allele (Engelman et al., 2007;
Lutterbach et al., 2007), with erlotinib, and evaluated
p-EGFR, EGFR, p-MET and MET levels. In contrast
to the EGFR-dependent cell lines tested, pharmacolo-
gical inhibition of EGFR did not diminish MET
expression in this cell line (Figure 3f).
Previous studies suggested that activated EGFR
can directly induce phosphorylation of MET (Bergstrom
et al., 2000; Jo et al., 2000). To evaluate the effect of
EGFR activation on MET in NSCLC, we stimulated
A549 cells with EGF with or without erlotinib.
Phosphorylated EGFR was detected 30min after ligand
stimulation, and EGFR activation was inhibited with
erlotinib (Figure 3g). EGFR levels decreased 12 h after
the addition of EGF, which may have been a result of
receptor internalization. EGF stimulation triggered rises
in p-MET levels at 30min, suggesting that EGFR
directly activated MET. p-MET levels remained detect-
able 6 h after EGF stimulation. Prolonged exposure
(24 h) to EGF resulted in increased levels of MET
protein (Figure 3h).
EGFR-mediated invasion of NSCLC cells is MET
dependent
To show that MET activation increases invasiveness in
NSCLC and that this can be abrogated with the MET
TKI, PHA-665752, we treated A549 and HCC827
tumor cells with the MET ligand HGF alone or with
PHA-66752. Cell invasion was measured using Matrigel-
coated Boyden chambers. In both cell lines, HGF
stimulation resulted in a signiﬁcant increase in invasive-
ness, and this was inhibited with the addition of PHA-
665752 (Po0.05; Figure 4a). As EGFR activation has
been shown to modulate tumor cell invasion in multiple
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cell types including NSCLC (Hamada et al., 1995;
Damstrup et al., 1998), we investigated whether EGFR
activation’s effect on tumor cell invasion is MET
mediated. We stimulated A549 cells with EGF alone
or with erlotinib or the MET TKI, PHA-665752. EGF
induced a twofold increase in cell invasion compared
with control (Po0.05; Figure 4b). The addition of
erlotinib or PHA-665752 reduced the number of
invading cells to control levels, indicating that EGFR-
driven cell invasion is MET dependent. In a similar
experiment using HCC827 cells, in which EGFR is
constitutively activated, EGF stimulation did not in-
crease tumor cell invasiveness compared with control
levels; however, pharmacological inhibition of EGFR or
MET activation signiﬁcantly reduced the number of
invading cells (Figure 4c; Po0.05).
To further elucidate the mechanism by which
EGFR-activating mutations drive tumor cell invasion,
we transfected HCC827 cells with EGFR-, HIF-1a-, or
MET-targeting siRNA and evaluated cell invasion.
Knockdown of EGFR, HIF-1a, or MET resulted in
decreased invasive capacity (Figure 4d; Po0.001),
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whereas control siRNA did not affect invasive capacity.
To conﬁrm that decreases in the number of invasive cells
after erlotinib or siRNA treatment was indeed do to
changes in the invasive capacity of tumor cells and not
because of changes in cell viability or proliferation, we
separately performed a similar study in which the
number of invasive cells was normalized to the number
of cells that did not invade through the chamber
(Supplemental Figure 1). These data were in agreement
with the ﬁndings shown above.
To determine whether MET inhibition impacted
cellular growth, we conducted MTS (3-(4,5-dimethylthia-
zol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt) assays in the presence of
increasing concentrations of erlotinib or PHA-665752.
HCC827 cells were sensitive to the EGFR inhibitor
erlotinib (IC50 o10nM), whereas H1993 and A549 cells
were less sensitive (Supplemental Figure 2). None of the
three cell lines were sensitive to PHA-665752 at
concentrations as high as 10mM. This suggested that
invasiveness but not cell survival was MET dependent in
these cell lines.
Hypoxia-induced invasiveness of NSCLC cells
is MET dependent
Previous studies show that hypoxia increases the
invasive capacity of tumor cells (Cuvier et al., 1997).
Therefore, we investigated whether MET activation
mediates hypoxia-induced invasiveness of tumor cells.
A549 cells were plated in Matrigel-coated Boyden
chambers and incubated in normoxia (21% oxygen) or
hypoxia (0.1% oxygen) with or without erlotinib or
PHA-665752. Hypoxia enhanced tumor cell invasion
more than 2.5-fold (Po0.001). Erlotinib caused a
moderate decrease in tumor cell invasiveness, whereas
MET inhibition reduced hypoxia-induced tumor cell
invasion to levels below baseline (Figure 5a; Po0.001).
To examine the role of HIF-1a in this pathway, we
stably transfected A549 cells with a variant form of
HIF-1a (HA- HIF-1a P402A;P564A) that is constitu-
tively stabilized in normoxia because of proline to
alanine substitutions at the VHL binding site critical for
HIF-1a polyubiquitination and degradation (Masson
et al., 2001; Hu et al., 2003; Kim et al., 2006). Expression
of the HIF-1a variant augmented MET production
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(Figure 5b) and was associated with enhanced tumor cell
invasion (Po0.05; Figure 5c). PHA-665752, but not
erlotinib, reduced the number of invading cells to below
baseline values (Po0.05). These ﬁndings were consistent
with MET being a downstream mediator of HIF-1a-
mediated invasiveness in thse cells.
We examined the impact of WT and mutated EGFR,
and the role of MET, on invasiveness in NIH-3T3 cells.
NIH-3T3 cells were stably transfected with control GFP
plasmid, WT EGFR or EGFR bearing the L858R
mutation or the deletion mutant DL747-5752del. A
greater than twofold increase in HIF-1a levels was
observed in cells bearing the DL747-5752del deletion
(P¼ 0.02) or the L858R mutation (P¼ 0.01) compared
with GFP transfected controls (Figure 5d). RT–PCR
analysis revealed that NIH-3T3 cells expressing L858R
expressed increased MET mRNA levels compared with
GFP transfected controls (P¼ 0.02; Figure 5e). NIH-
3T3 cells stably transfected with control GFP plasmid,
WT EGFR, or EGFR bearing the L858R mutation or
the deletion mutant DL747-5752del were allowed to
invade Matrigel-coated Boyden chambers with or with-
out PHA-66752. Cells expressing WT or activated
EGFR had enhanced invasive capacity compared with
cells transfected with GFP vector, and inhibition of
MET signiﬁcantly reduced the number of invasive cells
to near baseline values (Figure 5f).
Discussion
This study offers new insights into the mechanisms by
which EGFR mediates its tumorigenic effects and
provides new evidence that the HIF-1a/MET axis is
critical to regulating invasiveness induced not only by
hypoxia but by EGFR as well, thus illustrating the
convergence of two pathways known to drive invasive
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Figure 5 Hypoxia-induced tumor cell invasion is MET dependent. (a) A549 cells were seeded onto growth factor-reduced Matrigel-
coated invasion chambers and incubated in normoxia or hypoxic (1% O2) conditions with or without erlotinib (1mM) or PHA-663225
(1mM) for 24 h, and the number of invading cells was quantiﬁed. Hypoxia-induced invasion was MET dependent but EGFR
independent. Bars, % s.d.; *Po0.05; **Po0.001. (b) A549 cells were transfected to overexpress a degradation-resistant HIF-1a
variant (HA- HIF-1a P402A;P564A), as shown by immunoblot. Increased HIF-1a was associated with enhanced MET expression.
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Activated EGFR regulates MET through HIF-1a
L Xu et al
2622
Oncogene
tumor growth. In NSCLC cells, we showed that EGFR
activation, by either EGFR kinase mutations or ligand
binding, increased MET levels through a hypoxia-
independent mechanism involving expression of HIF-
1a. MET was uncoupled from EGFR regulation,
however, in a cell line with MET ampliﬁcation, a
ﬁnding consistent with the recently described role of
MET ampliﬁcation in EGFR TKI resistance (Engelman
et al., 2007). Overexpression of a constitutively active
form of HIF-1a also abrogated the regulation of MET
levels by EGFR. Therefore, though this study shows
that EGFR signaling can regulate MET levels and that
MET can be downstream mediator of EGFR-induced
invasiveness, it also suggests that there are ways by
which this pathway may be bypassed.
We initially investigated MET levels in tumor speci-
mens from 202 NSCLC patients by immunohistochem-
istry and observed increased levels of MET in tumors
with EGFR-activating mutations compared with tumors
with WT EGFR. Consistent with these ﬁndings, we
observed elevated levels of MET in a previously
described transgenic murine model of NSCLC with
lung-speciﬁc expression of an EGFR-activating muta-
tion. MET levels decreased signiﬁcantly after treatment
with the EGFR inhibitor erlotinib. We also observed
that NSCLC cell lines expressing mutated EGFR
exhibited elevated MET gene expression and protein
levels compared with cells with WT EGFR, and these
levels could be reduced by pharmacologically inhibiting
EGFR or with siRNA directed against EGFR. The
addition of an EGFR inhibitor decreasedMET mRNA,
indicating that in NSCLC cells, EGFR-activating muta-
tions augment MET expression at the transcriptional
level. Collectively, these results provide evidence that
activated EGFR has a critical role in regulating MET
expression in NSCLC tumor cells.
MET ampliﬁcation has been described in the setting
of gastric cancers (Smolen et al., 2006) and NSCLC
(Engelman et al., 2007). Engelman et al. (2007) reported
that among lung cancers with EGFR-activating muta-
tions,MET ampliﬁcation occurred in 22% of tumors that
developed resistance to geﬁtinib or erlotinib. Overall,
MET ampliﬁcation occurs in only 4% of all NSCLC cases
(Zhao et al., 2005), whereas high levels of MET and
p-MET are detectable in 36 and 21% of NSCLC cases,
respectively (Nakamura et al., 2007). MET expression
also has been shown to be regulated by hypoxia
(Pennacchietti et al., 2003). Here, we found evidence that
EGFR is a key regulator of MET levels in cells without
MET ampliﬁcation, and that this occurs through hypoxia-
independent regulation of HIF-1a. By contrast, in H1993
cells bearing MET gene ampliﬁcation, EGFR blockade
did not result in a reduction in MET levels, suggesting
that MET ampliﬁcation resulted in an uncoupling of
MET protein levels from EGFR regulation.
Ligand-induced phosphorylation of EGFR has been
shown to induce rises in HIF-1a in a cell type-speciﬁc
manner. We observed that HIF-1a levels were elevated
in NSCLC cell lines bearing EGFR mutations even in
the absence of added ligand, and that treatment with
an EGFR inhibitor diminished HIF-1a expression.
Although this study did not speciﬁcally address the
regulation of angiogenic factors such as VEGF, these
ﬁndings are consistent with recent studies that EGFR
regulates angiogenic factors, at least in part, through
HIF-1a-dependent mechanisms (Swinson et al., 2004;
Luwor et al., 2005; Pore et al., 2006; Swinson and
O’Byrne, 2006). Studies designed to elucidate the
mechanism by which EGFR-activating mutations reg-
ulate HIF-1a levels are ongoing.
In addition to enhancing MET levels, EGFR activa-
tion resulted in increases in MET receptor phosphoryla-
tion within 30min of EGF stimulation, an effect
blocked by erlotinib. Similar observations have been
made with other cell types (Bergstrom et al., 2000; Jo
et al., 2000); these and other published data support the
idea that EGFR may directly phosphorylate MET
(Bergstrom et al., 2000; Jo et al., 2000). Hypoxia is a
known regulator of HGF, presumably through HIF-1a
(Ide et al., 2006). It is feasible that EGFR-activating
mutations promote HGF production through HIF-1a.
Collectively, these data suggest that EGFR/HIF-1a
activation may not only regulate MET levels, but may
also impact MET signal transduction through other
mechanisms.
We investigated the consequences of EGFR-regulated
MET. We observed that the invasiveness (Figure 4)
but not survival (Supplemental Figure 2) of NSCLC
cells bearing EGFR-activating mutations was MET de-
pendent, as pharmacological inhibition or siRNA
directed against MET abrogated cell invasion. Invasive-
ness and MET levels were reduced by siRNA knock-
down of HIF-1a, whereas EGFR levels were unaffected;
indicating that MET is downstream of HIF-1a and
EGFR. We observed that EGF- and hypoxia-induced
invasiveness were both MET dependent, and that
heterologous expression of a constitutively active form
of HIF-1a induced invasiveness that was independent
of EGF stimulation but remained MET dependent
(Figure 5). Furthermore, heterologous expression of
wild-type or mutated EGFR in NIH 3T3 ﬁbroblasts
increased invasiveness in an MET-dependent manner,
providing further evidence that EGFR-mediated
invasiveness is mediated at least in part by MET. These
results support a model in which either hypoxia or
EGFR activation can drive invasiveness by converging
on a common HIF/MET pathway, which appears to
be separable from EGFR-induced survival and proli-
feration. MET ampliﬁcation appears to provide one
route for circumventing this pathway. Others will
likely emerge, and these ﬁndings do not exclude the
likelihood that other pathways contribute to the
invasive phenotype.
Our ﬁndings that EGFR can regulate MET levels
through hypoxia-independent regulation of HIF-1a,
and that MET is a downstream mediator of both
EGFR- and hypoxia-induced invasivenss, have impor-
tant clinical and biological implications. Even for
tumors thought to be primarily driven by the EGFR
pathway (that is with activating EGFR mutations),
targeting of the MET pathway in combination with
EGFR blockade may further reduce tumor invasiveness
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beyond the effect of EGFR inhibition alone, in addition
to the previously noted potential beneﬁt of preventing
the emergence of resistance through MET ampliﬁcation
(Engelman et al., 2007). It also raises the question of
whether other tyrosine kinases may regulate MET in a
similar manner in NSCLC and other diseases. Finally,
the observation that the EGFR and hypoxia converge
on the HIF-1a/MET axis suggests that there may be
additional overlap in the mechanisms by which EGFR
and hypoxia promote malignant behavior and thera-
peutic resistance.
Materials and methods
Cell lines
Drs John Minna and Adi Gazdar (UT Southwestern Medical
School, Dallas, TX, USA) provided H3255, H1975, H1993,
and HCC827 cells. A549 and Calu-6 were obtained from the
ATCC (Rockville, MD, USA). NIH-3T3 cells expressing WT
EGFR or EGFR bearing the L858R mutation or the deletion
mutant DL747-S752del (Shimamura et al., 2005) were obtained
from Dr Jeffrey Engelman (Dana-Farber Cancer Institute) and
were maintained in 10% FBS DMEM containing 1mg/ml
puromycin.
Mice
Animals were treated in accordance with the guidelines of the
US Department of Agriculture and the NIH. KrasLA1 mice
(Johnson et al., 2001) were obtained from Dr Tyler Jacks
(Massachusetts Institute of Technology, Cambridge, MA,
USA). CCSP-rtTA transgenic mice (obtained from J Whitsett
at The University of Cincinnati, Cincinnati, OH, USA) were
bred with Tet-op-hEGFR L858R-Luc to yield mice with lung
tumors driven by EGFR activation (Ji et al., 2006). At 6
months of age, lungs were collected. Animals bearing EGFR-
driven lung tumors were treated with vehicle (1% Tween-80;
Sigma-Aldrich, St Louis, MO, USA), or erlotinib (50mg/kg/
day) by gavage for 48 h.
Gene expression analysis
Affymetrix GeneChip Human Genome U133A (HG-U133A)
was used to perform gene expression analysis on 53 gene arrays
of NSCLC cell lines prepared by John Minna and colleagues
(UT Southwestern, Dallas, TX, USA; (Zhou et al., 2006).
CEL-type data ﬁles were obtained from NCBI-GEO dataset
GSE4824 (NCBI-GEO, 2007). CHIP (2007) software (http://
biosun1.harvard.edu/complab/dchip/) was used to generate probe-
level gene expression, median intensity, percentage of probe set
outliers, and percentage of single probe outliers (Lin et al., 2004).
Information ﬁles, including the HG-U133A gene information
ﬁles and Chip Description Files, were downloaded from the
Affymetrix web site. CEL and other data ﬁles were extracted.
Array images were inspected for contamination and bad
hybridization. Normalization was performed using the invar-
iant-set normalization method (Li and Hung Wong, 2001).
Model-based expression and background subtraction using the
5th percentile of region (perfect match only) was completed by
checking for single, array, and probe outliers. In the array
analysis and clustering, array outliers were treated as missing
values and no log transformation was performed. Comparison
within dCHIP of the WT EGFR vs mutated EGFR groups
using a more than 1.2-fold change in gene expression, a 90%
conﬁdence interval for fold change, and a 90% present call
yielded one probeset for MET (203510_at). Data were further
analyzed using GraphPad software (version 5, GraphPad
Software Inc., La Jolla, CA, USA).
Detection of HIF-1a, MET, and EGFR
Protein lysates were extracted using RIPA buffer (50mM Tris–
HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 1% Triton X-100,
1% sodium deoxycholate, and 0.1% SDS, and protease
inhibitors. Protein (60 mg) was used for western blotting.
Antibodies against EGFR (Y1068, Cell Signaling Technology
Inc., Danvers, MA, USA), EGFR (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) MET (Santa Cruz), HIF-1a
(Pharmingen, San Diego, CA, USA), b-actin (Sigma), and
vinculin (Sigma) were used. HIF-1a, p-EGFR, MET, and
p-MET ELISAs were obtained from R&D systems
(Minneapolis, MN, USA).
RNA isolation and RT–PCR
HCC827 cells were treated with complete media with or
without 1mM erlotinib for 12 h. Total RNA was extracted
using Trizol (Life Technologies, Carlsbad, CA, USA), and
puriﬁed with the RNeasy kit (Qiagen, Hilden, Germany). We
used SuperScriptTM III RNase H-Reverse Transcriptase
(Invitrogen, Carlsbad, CA, USA) to convert RNA into cDNA.
The oligonucleotide primers used were published previously
(Shimazaki et al., 2003).
Plasmids and transfections
HIF-1a cDNA (OriGene Technologies Inc., Rockville, MD,
USA) was subcloned into the pcDNA3.1 vector with a ﬂag
tagged in the N-terminal, and the HIF-1a mutant with proline
to alanine substitutions positions 402 and 564 (HA- HIF-1a
P402A;P564A), which are known VHL-binding sites, was
constructed as described (Kim et al., 2006). This form is
stabilized in normoxia because of the loss of VHL-mediated
polyubiquitination and subsequent degradation (Masson et al.,
2001; Hu et al., 2003). For siRNA transfections, HCC827 cells
were transfected with siRNA targetting EGFR, MET, HIF-1a
and control siRNA at a ﬁnal concentration of 100 nM using
Dharmafect 1 transfection reagent (Dharmacon, Lafayette,
CO, USA). Protein was isoloated after 72 h. Transfected cells
were plated for invasion assays after 48 h.
Invasion assay
We seeded 2.5 104 cells in the upper chamber of 24-well BD
Biocoat growth factor reduced Matrigel invasion chambers
(8.0 mm pore, Becton Dickinson, Bedford, MA, USA) with 0%
FBS media and added media containing 10% FBS to the lower
chamber. After 24 h, cells in the upper chamber were removed
by scraping. Cells that migrated to the lower chamber were
stained and counted using bright-ﬁeld microscopy under a
low-power ( 40) objective. PHA-663225 was obtained
from Pﬁzer (New York, NY, USA).
Clinical specimens
Tissue specimens from 202 surgically resected lung carcinomas
were obtained from the Lung Cancer Specialized Program of
Research Excellence (SPORE) Tissue Bank at The University
of Texas MD Anderson Cancer Center (Houston, TX, USA).
Two hundred and two specimens had known EGFR status.
Microarrays for each specimen were created with three cores
from formalin-ﬁxed, parafﬁn-embedded blocks. All specimens
were of pathologic TNM stages I–IV according to the revised
International System for Staging Lung Cancer (Beadsmoore
and Screaton, 2003).
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Immunohistochemistry staining
Using parafﬁn-embedded tissue sections, antigen retrieval was
performed by steaming in citrate buffer (pH 6.0). Endogenous
peroxidases were blocked using 3% H2O2. After protein
blocking, slides were incubated with anti-HGFR (1:50; R&D
Systems), washed, and incubated with a Universal
LSABþKit/HRP, visualization kit (DakoCytomation, Car-
pinteria, CA, USA). For tumor sections from transgenic
animals, antigen retrieval and blocking was performed as
above. Slides were incubated in 1:100 anti-mouse MET
antibodies (Santa Cruz) and then in secondary antibody
(Jackson Research Laboratories, Bar Harbor, ME, USA).
NSCLC specimens were used as positive controls for MET
staining. As a negative control, we followed the above
procedure omitting the primary antibodies. For quantiﬁca-
tion, each specimen was evaluated using an intensity score
(0, 1, 2, or 3) and an extension percentage (Yang et al.,
2008). The ﬁnal staining score was the product of these two
values. An average from the three cores was obtained for
each specimen.
Statistics
Student’s t-tests were performed using two-tailed tests with
unequal variance for Gaussian distributed data. For statistical
analysis of clinical specimens, Wilcoxon rank-sum tests were
used when comparing continuous variables between mutation
groups. To correlate mutation and other discrete covariates,
we used a chi-square test or Fisher’s exact test. Two-sided
P-values p0.05 were considered signiﬁcant.
Accession numbers
SNP and CGH raw data are available in the Gene Expression
Omnibus (GEO) database: GEO accession GSE4824 (http://
www.ncbi.nlm.nih.gov/geo/).
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ABSTRACT 
BACKGROUND: Estrogens exert physiological effects through two estrogen receptor (ER) 
subtypes, ERα and ERβ, which belong to the nuclear receptor family of ligand-activated 
transcription factors. The human ERβ variant ERβ2 is expressed at higher levels than ERβ1 
in many breast cancer cell lines and breast tumours. Increasing evidence supports the 
hypothesis that ERβ2, in contrast to ERβ1, is associated with aggressive phenotypes of 
various cancers. In this manuscript we determine phenotypes and molecular mechanisms of 
ERβ2, independent of ERα and ERβ1, in breast cancer cells. 
METHODS: The triple negative breast cancer (TNBC) cell line BT549 was used as model 
system. ERβ2 levels were modulated by transient overexpression or knockdown by small 
interfering RNA. Cell proliferation and invasion were assayed by the WST-1 cell proliferation 
assay kit and growth factor reduced BD MatrigelTM invasion chamber, respectively. 
GeneChip® Human Gene 1.1 ST Affymetrix microarrays were used to assay global gene 
expression. ERβ2 regulation of mRNA and protein levels of selected genes was investigated 
by qPCR and western blot analysis, respectively.  
RESULTS: In this study we show that ERβ2 is the dominant ER isoform in the BT549 cell 
line and promotes proliferation and invasion of this cell line. A total of 263 genes were 
identified as ERβ2-upregulated genes and 662 identified as ERβ2-downregulated genes. 
ERβ2-regulated genes were involved in cell morphology, DNA replication and repair, cell 
death and survival. We show that ERβ2 represses prolyl hydroxylase 3 (PHD3) gene 
expression and induces protein levels of the hypoxia induced factor 1 (HIF-1α) and MET.  
CONCLUSION: ERβ2 promotes cell proliferation and invasion of BT549 breast cancer 
cells. The invasive phenotype could potentially be mediated through transcriptional repression 
of PHD3, followed by up-regulation of the HIF1α-MET pathway. 
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INTRODUCTION 
Breast cancer is a common cause of cancer death among women. Estrogen plays crucial roles 
in breast cancer with most of the effects of estrogen mediated by estrogen receptors (ERs). 
For a long time, only one ER was thought to be the receptor that is responsible for mediating 
the effects of estrogen. This receptor is now called ERα [1]. However, in 1996, another ER, 
now named ERβ, was discovered [2]. Both receptors belong to the nuclear receptor 
superfamily [3, 4]. Like many other genes, ERβ is expressed as different isoforms, the 
functions of which need to be further studied in order to understand the physiological 
functions of ERβ. ERβ1 is considered as the full length ERβ. The most studied variant of 
ERβ, ERβ2, is the result of alternative splicing, the last 61 amino acids of ERβ1 being 
replaced by 26 unique amino acids from an alternative exon. ERβ2 lacks the intact ligand 
binding domain and activation function 2 (AF-2) core region. Since ERβ2 has an intact DNA-
binding domain and an intact N-terminal domain, including the AF-1 domain, ERβ2 could be 
directly involved in gene regulation.  
 
Several lines of evidence suggest that ERβ2 is associated with proliferation and invasion of 
cancer cells. This is in contrast to ERβ1, which is suggested to have anti-proliferative 
characteristics [5]. In breast, ovarian, prostate and non-small cell lung cancer, it was reported 
that the expression of ERβ2 is widespread and higher in cancer tissue compared to normal 
tissue [6-8]. Furthermore it was found that the expression of ERβ2 correlates with aggressive 
phenotypical features in breast, prostate and colon cancer [6, 9, 10]. Negative ERβ2 status is 
significantly correlated to longer overall survival time in case of the luminal subtype of breast 
cancer [10]. ERβ2 was correlated with poor prognosis and could promote cancer cell 
proliferation and invasion of prostate cancer [6, 11]. In line with the differential role of ERβ1 
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and ERβ2 with regard to cancer cell proliferation and invasion, ERβ2 increased proliferation 
and up-regulated factors involved in bone metastasis while ERβ1 inhibited these factors [5].  
 
HIF-1α is a major determinant of invasion and metastasis in a wide variety of tumor types. Its 
expression is regulated through modifications at the posttranslational level. In the presence of 
oxygen, three prolyl hydroxylase enzymes (PHD), PHD1, PHD2 and PHD3, can hydroxylate 
two proline residues (p402 and p564) of HIF-1α in the oxygen-dependent degradation 
domain. Hydroxylated HIF-1α can by recognized by the tumour suppressor von Hippel-
Lindau protein, which targets HIF-1α for degradation [12]. Tumour hypoxic areas show MET 
overexpression [13]. When MET is inhibited, hypoxia induced invasive growth was 
prevented [14]. The MET tyrosine-kinase receptor is an established mediator of cancer cell 
invasiveness. MET can increase the viability of cancer cells [14]. Previous findings showed 
that HIF-1α can regulate MET levels, with MET being an established mediator of cancer cell 
invasiveness [15].  
 
In this study, we focus on the role of ERβ2 for breast cancer cell proliferation and invasion 
using the BT549 cell line as a model that expresses endogenous ERβ2 but no ERα or ERβ1. 
We demonstrate that ERβ2 promotes cell proliferation and invasion in this model. We 
investigate ERβ2 dependent global effects on gene expression and suggest a model by which 
ERβ2 affects invasiveness of cells.  
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MATERIALS AND METHODS 
RNA isolation and cDNA synthesis 
Total RNA was extracted using the RNeasy kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. cDNA was synthesized from 1 µg of total RNA with Taqman 
Reverse Transcription reagents according to the standard protocol (Roche).  
 
qPCR 
Real-time PCR was performed with the SYBR Green I dye master mix (Applied Biosystems, 
Foster City, CA). qPCR reactions were performed using a 7500 Fast Real-Time PCR System 
(Applied Biosystems) applying the following conditions: 50°C for 2 min, 95°C for 10 min, 
followed by 40 cycles at 95°C for 15 sec and 60°C for 50 sec. mRNA expression levels were 
normalized relative to GAPDH or 36B4 internal control.  
 
Plasmids and transfection 
The ERβ2 cDNA was subcloned into the pcDNA3.1 vector with a flag tag at the N-terminus. 
For ERβ2 siRNA transfection, BT549 cells were transfected with siRNA targeting ERβ2 with 
a sequence 5’-GAAUGAAGAUGGAGACUCUUU-3’ (Thermo) or control siRNA (Sigma) at 
a final concentration of 100  nM using INTERFERinTM siRNA transfection reagent (Polyplus). 
For ERβ2 cDNA transfection, BT549 cells were transfected with pcDNA3-flag-ERβ2 or 
control pcDNA3-EV using lipofectamine®2000 according to manufacturer’s instructions 
(Invitrogen). 
 
Western blot analysis and ELISA assay 
Protein lysates were extracted using RIPA buffer (Sigma Aldrich). 30 mg of protein was used 
for western blot and ELISA analysis. Antibodies against MET (Santa Cruz Biotechnology 
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Inc., Santa Cruz, CA, USA), HIF-1α (Pharmingen, San Diego, CA, USA) and β-actin (Sigma) 
were used. HIF-1α ELISA was performed using a kit from R&D systems (Minneapolis, MN, 
USA). 
 
Immunohistochemistry staining 
Immunohistochemistry staining was performed as described previously [11]. 
 
Cell proliferation assay 
1000 cells per well were seeded onto 96-well plates. Cell proliferation was measured using a 
WST-1 kit (Roche Applied Science). 
 
Invasion assay 
24 hours after the transfection, approximately 2.5 × 104 cells were seeded in the upper 
chamber of 24-well BD Biocoat growth factor reduced Matrigel invasion chambers (8.0  µm 
pore, Becton Dickinson, Bedford, MA, USA) with 0% FBS media. Medium containing 10% 
FBS was added to the lower chamber. For ERβ2 siRNA and control siRNA transfection, cells 
in the upper chamber were removed by scraping after 30h; for ERβ2 cDNA and control 
transfection, cells in the upper chamber were removed after 24h. Cells that migrated to the 
lower chamber were fixed, stained and counted under a microscope.  
 
Gene Expression Microarray Analysis 
Total RNA from three biological replicates were hybridized to Affymetrix Human Gene 1.1 
ST arrays, which contain probes for 33299 gene sequences. Experimental steps such as probe 
synthesis, hybridization and scanning were done according to the Affymetrix protocol 
(www.affymetrix.com). Pre-processing for background correction/normalization was 
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performed in the Affymetrix Expression Console using the Robust Multichip Average (RMA) 
method[16]. Two-tailed Student's t-test was used to derive p-values, and the false discovery 
rates were estimated using the q-value. A cut-off fold change of at least 1.5 and p value < 0.05 
were used to define differentially regulated genes. The q-value, representing the false 
discovery rate, was less or equal to 0.1.  
To derive genes as input for pathway analysis the following cut-offs were applied; fold 
change of ≥ 2, p value < 0.05 and q value ≤ 0.1. The Ingenuity Pathway Analysis (IPA) 
software (www.ingenuity.com) was used for this analysis. The entire IPA core analyses was 
performed based on information in the Ingenuity Pathway Knowledge Base (IPKB), which 
derives information from known relationships of molecules, functions and interactions of 
genes published in the literature.  
IPA analysis identified pathways that were most significantly changed upon ERβ2 knock 
down. Associated network functions and molecular functions are two of the categories used 
for enrichment testing within IPA. Biological functions were ranked according to the 
significance of that function to the network.  
Fisher’s exact test was used to derive the p-values in IPA. 
 
Statistics 
Student's t-tests were performed using two-tailed tests with unequal variance. 
 
RESULTS 
The TNBC cell line BT549 expresses high levels of ERβ2  
We screened the expression of ERβ2 in a panel of 8 breast cancer cell lines, including 2 ER-
positive luminal (MCF-7 and MDA-MB-175), 3 HER2-positive (SK-BR-3, HCC1569, and 
MDA-MB-453) and 3 TNBC (MDA-MB-231, BT549 and Hs578T) cell lines. The ERβ2 
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mRNA was highly expressed in the 2 TNBC cell lines, BT549 and MDA-MB-231. The 
highest level of endogenous ERβ2 expression was observed in the BT549 cell line (Figure 1). 
The mRNA expression levels of ERβ1 and ERα in this cell line is undetectable (data not 
shown).  
 
Depletion of ERβ2 inhibits cellular proliferation and invasion in vitro 
We used siRNA to silence ERβ2 expression. Successful knockdown of ERβ2 was confirmed 
at both the mRNA and protein levels (Figures 2A and 2B). Furthermore, this experiment 
revealed that ERβ2 is mainly localized to the cytoplasm of cells (Figure 2B, Left panel). 
Interestingly, ERβ2 knockdown inhibited cell proliferation of BT549 cells (Figure 2C). 
Moreover, ERβ2 silencing decreased the number of invading cells per 20 × field from 34.6 ± 
9.0 in the control siRNA group to 13.4 ± 5.5 in the ERβ2 siRNA treated group (Figure 2D) (p 
< 0.05).  
 
ERβ2 overexpression confers a more proliferative and invasive phenotype in vitro 
To further confirm the effect of ERβ2 on cellular proliferation and invasion, we investigated 
these phenotypes after exogenous ERβ2 overexpression. Successful overexpression of ERβ2 
was confirmed by western blot analysis (Figure 3A). Importantly, ERβ2 overexpression 
promoted cell proliferation in BT549 cells (Figure 3B). Additionally, BT549 cells 
overexpressing ERβ2 displayed a more invasive phenotype with 55.0 ± 5.0 cells migrating 
through the chamber compared to 9.2 ± 2.7 cells for the control cells (Figure 3C) (p < 0.001). 
These results further support the link between ERβ2 expression and the cellular proliferation 
and invasion.  
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ERβ2 influences global gene expression  
To gain insight into ERβ2 regulated transcriptional networks, we determined gene expression 
profiles for BT549 cells upon ERβ2 knockdown. We identified 662 genes, applying a false 
discovery rate of less or equal to 0.1, as up regulated (fold change equal or greater than 1.5, p 
< 0.05) while the expression of 263 genes was repressed (fold change equal or less than 1.5, p 
< 0.05) upon ERβ2 knockdown. Network analysis revealed the top three ranked networks 
regulated by endogenous ERβ2 in BT549 cells as cell morphology, DNA replication and 
repair, cell death and survival and cell morphology (Table 1A). Molecular and cellular 
functional classification analysis in IPA shows how the alterations of gene expression were 
predicted to disrupt various molecular and cellular functions. For our data set, the top 5 
highlighted molecular and cellular functions were cell cycle, cell death and survival, 
morphology, development and organization, which were represented by 4 to 8 genes with p-
values between 1.94× 10− 3–4.57× 10− 2 and 1.94× 10− 3–3.63× 10− 2 after ERβ2 knockdown 
(Table 1B).  
 
Consistent with the anti-proliferative effect of ERβ2 depletion, Cyclin E/A (CCNE2/CCNA2) 
were down regulated by 1.3 and 1.4 fold, respectively, with a concomitant increase in the 
expression of p21WAF1/CIP1 (CDKN1A) by 1.5 fold.  
 
Validation of gene expression profiling data by qPCR  
qPCR analysis was performed to confirm changed expression of 6 genes (HOXA7, GAB1, 
RECK, TGFB3, E2F2 and PHD3) identified as being regulated by ERβ2 in the gene 
expression profiling analysis. qPCR results were consistent with the microarray data, thus 
demonstrating the accuracy of the array approach (Figure 4). 
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ERβ2 promotes BT549 cell invasion potentially through repressing PHD3 followed by 
up-regulation of the HIF-1α-MET pathway  
One of the genes, the expression of which was up-regulated, by knockdown of ERβ2 was 
PHD3 (Figure 5A, Left Panel). Importantly, the PHD3 mRNA level was reduced by 
overexpression of ERβ2 (Figure 5A, Right Panel), further establishing a link between ERβ2 
and PHD3. As PHD3 has been shown to regulate HIF-1α stability [17], we next determined if 
the HIF-1α - MET pathway was regulated by ERβ2 as the HIF-1α - MET pathway has been 
shown to mediate cellular invasion in other systems [15]. Interestingly, knockdown of ERβ2 
decreased HIF-1α levels while overexpression of ERβ2 increased HIF-1α and MET levels 
(Figure 5B). Changes in HIF-1α protein levels were further confirmed by ELISA (Figure 5C).  
 
DISCUSSION 
 
Breast cancer is a disease with different morphological features and clinical behaviours, and 6 
intrinsic subtypes (Luminal A, Luminal B, normal breast like, HER2 enriched, basal-like 
breast cancer and Claudin low breast cancer) have been defined according to microarray 
based classification [18]. Approximately 60-80% of basal-like breast cancers correspond to 
TNBC, which are characterized by a lack of expression of ERα, progesterone receptor (PR) 
and HER2 overexpression. In our present study, we used BT549 due to the high endogenous 
ERβ2 expression. BT549 is a TNBC cell line. TNBC constitutes 10–25% of all breast 
cancers, has aggressive phenotypes and displays the worst prognosis among breast cancer 
subtypes. It affects mostly younger age groups and there is a lack of effective targeted 
therapies. TNBC lacks predictive biomarkers and often develop distant metastases in distant 
tissues such as brain and lung. In the present study, we demonstrate that ERβ2 is highly 
expressed in TNBC cells and promotes cell proliferation and invasion, which is in line with 
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the aggressive behavior of TNBC.  
Estrogen signalling via ERs has been linked to the promotion of breast cancer. While ERα 
has been shown to generally promote proliferation in breast cancer, ERβ1 has been suggested 
to display anti-proliferative properties including in breast cancer [19]. Less is known about 
the role of the ERβ2 variant in breast cancer. One reason for this lack of knowledge is that 
ERβ2 is only expressed in humans and primates and but not in rodents, making it difficult to 
study it in the context of an animal model. The focus of this study was to elucidate the role of 
ERβ2 in breast cancer cells. Furthermore, since cross talk between ERα and ERβ1 and ERβ2 
signalling has been demonstrated, we focused on the role of ERβ2 expressed alone. 
Expression of ERβ variants in breast cancer has been analyzed at the mRNA or protein level 
in several clinical materials. However, the extent to which breast tumours express ERβ2 
alone is still unclear. Studies of ERβ1 and ERβ2 in cell lines have been limited by difficulties 
in identifying cell lines that express endogenous ERβ. In this study we identify a breast 
cancer cell line that exclusively expresses endogenous ERβ2.  
 
The data shown in this study relies on a single siRNA against ERβ2. However, we observed 
the opposite phenotypes in a system where ERβ2 was overexpressed, supporting the 
connection between ERβ2 and proliferation and invasion. Furthermore, effects on PHD3 
mRNA levels as well as HIF-1α protein levels were opposite between ERβ2 siRNA treated 
and ERβ2 overexpressing cells, strengthening their connection to ERβ2 signalling. For MET, 
the effect of knock down of ERβ2 was less clear. In addition, transfection of two siRNA 
oligos from Sigma targeting both ERβ1 and ERβ2 inhibited proliferation and invasion of 
BT549 cells compared to transfection with control siRNA (data not shown). As the mRNA 
level of ERβ1 is undetectable in this cell line (data not shown), those siRNA oligos should 
target ERβ2 in this system. 
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We used gene expression profiling to approach the molecular mechanisms associated with the 
proliferative and invasive properties of ERβ2 and identified changes in pathways and 
molecular classes associated with cancer, cell cycle, cell survival and cell death compatible 
with a role of ERβ2 in cellular proliferation and invasion. Our data shows that endogenous 
ERβ2 is mainly localised to the cytoplasm of BT549 cells (Figure 2B, Left panel). This 
suggests that ERβ2 effects on gene regulation are indirect. How ERβ2 exerts its effects in 
BT549 cells, and other cell lines where ERα and ERβ1 are not expressed, remain to be 
determined. In systems where ERβ2 is co-expressed with ERα we have shown that ERβ2 
induces proteasome-dependent degradation of ERα, presumably through the formation of 
ERβ2/ERα heterodimers [20]. In this case ERβ2-mediated degradation of ERα is one 
mechanism whereby expression of ERβ2 inhibits recruitment of ERα to the estrogen-
responsive promoters, leading to suppression of ERα-regulated gene expression. We are only 
aware of one published study addressing changes in gene expression profiles in response to 
expression of ERβ2 alone [21]. In this study, Hs578T TNBC cells were engineered to express 
ERβ2. This study reported that expression of ERβ2 had no effects on gene expression [21]. 
Furthermore, we have observed that ERβ2 does not modulate gene expression in HEK293 
cells engineered to stably express ERβ2 alone (unpublished data).  
 
Pathway analysis can serve as a biological verification of non-random biological differences, 
especially if the results are supported by an experimental hypothesis and additional data. 
Additionally, based on IPA analysis, new hypothesis can be derived. Our IPA analysis 
showed that ERβ2 is involved in cell morphology, cell cycle, cell death and survival. In 
general, the gene expression profiling revealed changed expression of a very limited number 
of genes that could be causative for the observed phenotypes (data not shown). However, as 
our studies focused on a snapshot of gene expression, it is possible that we missed genes, the 
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changed expression of which, influence the phenotype. Future studies should address changes 
in gene expression at additional time points following knock down of ERβ2.  ERβ2 promoted 
cell proliferation could be caused by the observed down-regulation of CCNE2/CCNA2 and 
up-regulation of CDKN1A. Knockdown of ERβ2 also down regulates the Wilms tumor-1 
(WT-1) mRNA which is a transcription factor that plays an important role in cellular 
development, cell survival and angiogenesis [22]. 
 
In this study we propose that the invasive phenotype associated with ERβ2 expression could 
potentially be via repressing of PHD3 followed by up-regulation of the HIF-1α-MET pathway 
or by directl regulation of MET（Figure 6). In line with this, PHD3 has been shown to exert 
tumour-protective functions and inhibits tumour growth in pancreatic cancer [23]. In a recent 
study, Thomas et al shows that ERβ1 represses basal-like breast cancer epithelial to 
mesenchymal transition by destabilizing epidermal growth factor receptor (EGFR) where the 
mesenchymal state represents a state of invasion [24]. In our system, we observe that ERβ2 
increases EGFR protein levels (data not shown). Since the HIF-1α-MET pathway is known to 
be regulated by EGFR, this might represent an alternative mechanism for ERβ2 regulation of 
the HIF-1α-MET pathway and subsequent invasion [15].  
 
In summary, we demonstrate that ERβ2 promotes cell proliferation and invasion when 
expressed in the absence of ERβ1 and ERα. To further our understanding of the clinical 
relevance of ERβ2, the role of ERβ2 needs to be examined in human breast cancer specimens. 
It will be important to generate mouse models that express ERβ2 in different tissues. 
Furthermore, although ERβ2 does not bind tested ER ligands, it is possible that compounds 
that inhibit its function or target genes can be identified, thus providing potential therapeutic 
agents for breast cancers that express ERβ2.   
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FIGURE LEGENDS 
 
Figure 1. The TNBC cell line BT549 has the highest endogenous expression of ERβ2 
Analysis of ERβ2 mRNA levels in ER+/PR+/HER2- breast cancer cell lines (MCF-7 and 
MDA-MB-175), ER-/PR-/HER2+ breast cancer cell lines (SK-BR-3, HCC1569 and MDA-
MB-453) and TNBC cell lines (MDA-MB-231, BT549 and Hs578T) by qPCR. mRNA levels 
are normalized to GAPDH and mRNA levels are presented as means ± of relative fold with 
SD, with one corresponding to expression level in MCF-7 cells. 
 
Figure 2. Depletion of ERβ2 inhibits cellular proliferation and invasion. (A) ERβ2 siRNA 
down-regulates ERβ2 mRNA in BT549 cells. ERβ2 mRNA levels were determined by qPCR 
after transfection with control siRNA or siRNAs against ERβ2. Data are normalized to 36B4 
and shown as relative fold compared to siControl with SD.*p < 0.05. (B) ERβ2 siRNA down-
regulates ERβ2 protein in BT549 cells. Immunohistochemistry staining showing that the 
ERβ2 is located to the cytoplasm in BT549 cells and that the level is reduced after 
transfection with siRNA targeting ERβ2. (C) ERβ2 depletion reduces proliferation in BT549 
cells. BT549 cells were transfected with siRNA against ERβ2 or control siRNA. WST-1 
assays of cell metabolic activity as a measure of cellular proliferation were carried out at the 
indicated time points after siRNA transfection. Data are shown as means with SD. **p<0.01, 
***p < 0.001. Experiments were repeated twice. One representative experiment in shown. (D) 
ERβ2 depletion reduces invasion in BT549 cells. BT549 cells were transfected with siRNA 
against ERβ2 or control siRNA, and cell invasion was evaluated by the BD Biocoat growth 
factor reduced Matrigel invasion chambers assay. Data represent means with SD. *p < 0.05. 
Experiments were repeated twice. One representative experiment in shown.  
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Figure 3. ERβ2 overexpression confers a more proliferative and invasive phenotype in 
vitro. (A) Western blot analysis showing increased protein levels of ERβ2 after transient 
transfection with flag tagged ERβ2.  ERβ2 was detected by an anti-flag antibody. β-actin was 
used as a loading control. The arrow indicates the position of the overexpressed ERβ2 
protein. (B) ERβ2 overexpression promotes cell proliferation in BT549 cells. WST-1 assays 
of cell metabolic activity as a measure of cell proliferation were carried out at the indicated 
time points after transfection of flag tagged ERβ2 or empty vector, respectively. Ratio of 
absorbance to day2 is calculated. Data are shown as means of relative absorbance with SD. 
*p < 0.05, **p<0.01. Experiments were repeated twice. One representative experiment in 
shown. (C) ERβ2 overexpression promotes cell invasion in BT549 cells BT549 cells were 
transfected with flag tagged ERβ2 or empty vector, and cell invasion was evaluated by BD 
Biocoat growth factor reduced Matrigel invasion chambers assay. Data represent means with 
SD. ***p < 0.001. Experiments were repeated twice. One representative experiment in 
shown.  
 
Figure 4. Validation of gene expression profiling data by qPCR  
Real-time PCR analysis for a subset of genes from the same RNA as was used for the 
microarray analysis. mRNA levels are normalized to 36B4 and mRNA levels are presented as 
means ± of relative fold with SD, relative to control siRNA-treated cells. Fold changes 
derived from microarray analysis is presented as numbers below the bars. 
 
Figure 5. ERβ2 modulates levels of PHD3, HIF1α and MET in BT549 cells. (A) Top 
panel, BT549 cells were transfected with siRNA against ERβ2 or control siRNA, 
RNA was collected after 48h, and PHD3 levels were determined by qPCR assay, mRNA 
levels are normalized to 36B4, **P<0.005. Bottom panel, BT549 cells were transfected with 
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pcDNA3-flag tagged ERβ2 or an empty control vector. RNA was collected after 48h, and 
PHD3 levels were determined by qPCR assay, mRNA levels are normalized to 36B4. (B) 
BT549 cells were transfected with siRNA against ERβ2, a control siRNA, 
pcDNA3-flag tagged ERβ2 or an empty control vector. Protein lysates were collected and 
MET, and HIF-1α levels were evaluated by western blot analysis. β actin was probed as a 
loading control. (C) BT549 cells were transfected with siRNA against ERβ2, a non-targeting 
control siRNA, pcDNA3-flag tagged ERβ2 or an empty control vector. Protein lysates were 
collected and HIF-1α levels were evaluated by ELISA assay. **P<0.005.  
 
Figure 6. Proposed model of ERβ2 promoting cell proliferation and invasion in BT549 
ERβ2 abrogates the expression of PHD3. We hypothesize that the phenotypes associated with 
ERβ2 expression could potentially be via repressing of PHD3 followed by up-regulation of 
the HIF-1α-MET pathway or direct up-regulation of MET. 
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Table 1A Changed networks after knockdown of ERβ2 in BT549 cells 
 
 
Table 1B Changed molecular functions after knockdown of ERβ2 in BT549 cells 
Name p-value #Molecules 
Cell Cycle 1.94E-03-4.01E-02 5 
Cell Death and Survival 1.94E-03-4.46E-02 5 
Cell Morphology 1.94E-03-4.57E-02 8 
Cellular Development and Organization 1.94E-03-3.63-02 7 
Cellular Development 1.94E-03-3.79-02 4 
 
 
 
Top Networks  
ID  Associated Network Functions Score 
1 Cell Morphology, DNA Replication, Recombination and Repair, 
Developmental Disorder 
32 
2 Cancer, Reproductive System Disease, Cell Dearth and Survival 24 
3 Cell Morphology, Dermatological Diseases and Conditions, 
Developmental Disorder 
24 
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